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ABSTRACT 
Agents targeting colchicine-binding sites are recognised as valuable lead 
compounds in the development of new anticancer drugs. Although colchicine can 
effectively inhibit cell proliferation, its use as an anticancer agent has not been 
approved by the FDA due to its inherent toxicity. To develop colchicine-binding 
site targeting agents with low or no toxicity, in collaboration with Rajiv Gandhi 
Technical University of India, several chalcone derivatives were created and 
examined. Preliminary studies at the Lee Lab identified CTR-17 and CTR-20 as 
promising leads. Their anti-proliferative activities using three human breast 
cancer cell lines (MDA-MB468, MDA-MB231 and MCF-7) and two matching non-
cancer breast cell lines (184B5 and MCF10A) were initially determined. 
Subsequently, nine other cancer cell lines were used to assess the broad 
spectrum anti-proliferative effects of the CTR compounds. Data from this study 
showed that CTR-17 and CTR-20 preferentially kill cancer cells 10-25 times over 
non-cancer cells. Data obtained from flow cytometry, confocal microscopy and 
Western blotting showed that CTR-17 induced a prolonged mitotic arrest, leading 
to cancer cell death probably via apoptosis. I also found that both CTR-17 and 
CTR-20 inhibited tubulin polymerisation and bound to purified tubulin fibers with a 
dissociation constant of 4.58±0.95 µM and 5.09±0.49 µM, respectively. CTR-17 
and CTR-20 competitively inhibited the binding of colchicine to tubulin with an 
inhibitory concentration of 5.68±0.35 µM and 1.05±0.39 µM, respectively, 
suggesting that the CTR compounds bind to tubulin at a site partially overlapping 
the colchicine-binding site. Molecular docking studies confirmed this binding to 
occur via two and one hydrogen bonds between tubulin and CTR-20 and CTR-
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17, respectively. More interestingly, CTR compounds inhibit the proliferation of 
multi-drug resistant cell lines, which overexpress drug transporters involved in 
the efflux of clinically available microtubule targeting agents. In addition, the CTR 
compounds exhibit a synergistic relationship with paclitaxel in causing 
cytotoxicity to a P-glycoprotein overexpressing cell line. Therefore, these novel 
chalcone derivatives not only possess cancer-specific cell killing property but 
also the ability to exhibit similar cytotoxicity to both the multi-drug sensitive and 
resistant cells. Hence, CTR compounds possess substantial potential as safe 
and effective anticancer drugs. 
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1.0 Introduction 
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1.1 Background 
Chalcones are a group of compounds that are highly abundant in plants such as 
ferns (Pityrogramma calomelanos L.) and evergreen trees belonging to magnolia 
(Fissistigma lanuginosum Merr.), myrtle (Calythropsis aurea C.A. Gardner) and 
matico (Piper aduncum L.) families (Stanton et al. 2011). Chalcones are the 
precursor molecules to a wide variety of flavonoids and isoflavonoids and, 
chemically, they contain a three-carbon α, β unsaturated carbonyl system that 
joins two aromatic rings (Rahman 2011). Chalcones and their derivatives 
possess diverse pharmacological  activities, including antioxidant, anti-
inflammatory, antimicrobial, anti-HIV, antimalarial, anti-tubercular, anti-allergic 
and anticancer properties (Lawrence et al. 2006). Both synthetic and naturally 
occurring chalcones are investigated for their anti-proliferative ability, however 
their mechanism of action is vast and remains to be fully explored (Prabhakar et 
al. 2014). Chalcone-based compounds such as benzacetophenones contain a 
trimethoxyphenyl ring, similar to colchicine and podophyllotoxin, and have been 
reported to show potent cytotoxic properties by arresting cells in mitosis about 
300 times more efficiently than colchicine (Smith et al. 1988). Certain chalcone 
derivatives, including MDL-27048 (trans-1-(2,5-dimethoxy)-3-[4-(dimethylamino) 
phenyl]-2-methyl-2-propen-1-one), competitively inhibits the binding of colchicine 
and podophyllotoxin to tubulin. Hence, they are recognised as colchicine-site 
binding agents that have been shown to interact with tubulin reversibly and more 
rapidly than colchicine (Peyrot et al. 1992).  
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Microtubule-targeting drugs bind to tubulin via three major binding sites: the 
taxane, vinca and colchicine-binding sites. While the taxanes and the vinca 
alkaloids have been recognised as clinically successful drugs, agents binding to 
the colchicine-binding site including podophyllotoxin have not been used as 
anticancer therapeutics due to their extreme toxicities to normal tissues (Lu et al. 
2012).  
 
Many of the currently available microtubule-targeting drugs suffer from several 
limitations including drug-resistance, dose-limiting toxicities, complexities in 
synthesis, complicated formulations, scarcity and reduced bioavailability. 
Therefore, the search for novel microtubule-targeting agents has remained the 
priority for a number of years (Schmidt & Bastians 2007).  
 
Chalcones make an attractive drug scaffold because of their extremely simple 
skeleton and the ease of synthesis from acetophenones and substituted 
benzaldehydes (Lawrence et al. 2006). Structure-activity relationship (SAR) 
modifications and alterations can be performed easily on the chalcone structure 
(Prabhakar et al. 2014). The activity of this class of compounds is rendered 
mainly by the extended conjugation and high electrophilicity, while their potent 
antioxidant properties rely on the ability to completely delocalise the pi electrons 
(Awasthi et al. 2009; Cheng et al. 2000). Despite the identification of antimitotic 
chalcones in the 1980s, there are currently no chalcone derivatives that have 
reached the stage of human clinical trials as anticancer therapeutics. However, 
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preclinical studies hold promise, demonstrating minimal toxicities, rapid 
metabolism and effective inhibition of tumor growth and metastasis. In addition to 
the use of chalcones for other diseases such as ulcers, the abundance of 
chalcones in edible fruits suggest that they are well-tolerated by  humans 
(Jandial et al. 2014). Several chalcone derivatives are currently in various 
developmental stages as promising anticancer drugs. In collaboration with Rajiv 
Gandhi Technical University of India, we synthesized several chalcone 
derivatives and examined for their anticancer property. Preliminary studies in our 
lab identified CTR-17 and CTR-20 as the promising leads and major part of my 
work was focussed on elucidating the molecular mechanism of CTR-17 and the 
target of the CTR compounds.  
 
1.2 Objectives 
The specific aims of this study were: 
Aim 1: To evaluate the potential of CTR-17 as an effective and selective 
anticancer drug using a panel of cancer and non-cancer cell lines 
Aim 2: To determine the functional mechanism of CTR-17  
Aim 3: To determine the molecular target of CTR-17 and CTR-20  
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1.3 Microtubules as an anticancer drug target 
Microtubules (MTs) are ubiquitous cytoskeleton polymers composed of two 
spherical proteins, the α and β-tubulins, each with a mass of 55kDa. Linear 
polymers of these tubulin heterodimers are bound head-to-tail to form the 
protofilaments, which are then arranged in a parallel configuration to form each 
microtubule (Nogales 2000). The self-assembly of thirteen protofilaments to form 
the MTs and their association with diverse cellular factors are governed by the 
sequence and structure of the tubulin protein itself (Jordan et al. 1998). MTs 
perform multiple roles within the cells, including the maintenance of cell shape 
and structure, cellular transportation, cellular motility, faithful segregation of 
chromosomes and cell division. These roles rely on the ability of the microtubules 
to interact with the microtubule-associated proteins (MAPs), the expression of 
tubulin isotypes and their post-translational modifications (PTMs). MTs are 
dynamic polymers that alternate stochastically between phases of growth and 
shortening with periods of undetectable activity or “paused” periods that 
intervene both in vitro and in vivo. This non-equilibrium and agitated behaviour is 
known as “dynamic instability.” Although energetically unfavourable, this dynamic 
instability of the MT is fundamental to their diverse intracellular roles including the 
construction of the highly elegant mitotic spindle during cell division (Stanton et 
al. 2011; Nogales 2000).  
 
High concentrations of purified tubulin can be used to assemble MTs in vitro; 
however, the assembly of MTs in vivo is highly controlled and occurs via the 
centrosome, also known as the MT organization centre (MTOC) (Gould & Borisy 
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1977). During interphase, the MTs emanate from the centrally located 
centrosomes and projects towards the periphery of the cells. MTs are polar in 
nature due to the intrinsic heterogeneity of the MT ends. The plus (+) end of the 
MTs displaying the β-tubulin is responsible for the rapid growth. They may be 
located free in the cytoplasmic space or even reach the plasma membrane. On 
the other hand, the minus (-) end of the MTs displaying α-tubulin is more sluggish 
and usually embedded in the MTOC (Walker et al. 1988) (Figure 1).  
 
MT polymerization occurs in two steps: a nucleation phase that involves the 
formation of a polymerization nucleus, followed by a growth phase that 
constitutes the reversible and non-covalent addition of the tubulin subunits 
(Jordan & Wilson 2004). For net MT growth, the association of the tubulin 
subunits to the polymer end is faster than disassembly, and the depolymerisation 
of the MTs is counterbalanced by the addition of αβ heterodimers during 
equilibrium  (Nogales 2000; Valiron et al. 2001). Thus, MTs exhibit dynamic 
instability by alternating between episodes of shrinkage and growth, and this 
process is fueled by the binding and hydrolysis of GTP (Weisenberg et al. 1968). 
  
 
 
 
 
 
 
 
Figure 1: Microtubules and their intrinsic heterogeneity 
MTs contain about 13 protofilaments composed of αβ tubulin heterodimers, 
arranged to form a cylinder about 24 nm in diameter. Each protofilament 
comprises a plus-end that is fast growing and a minus-end which is slow in 
growth. γ- tubulin plays a role in the appropriate assembly of the MT. As the new 
dimer is added, guanosine-5’-triphosphate (GTP) at the E site of the β-subunit is 
hydrolysed to guanosine-5’-diphosphate (GDP). The figure was adopted from 
Conde & Cáceres (2009).  
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Both α and β monomers bind to one molecule of GTP. The GTP molecule that 
binds to the α-tubulin subunit via the N-site is neither hydrolyzed nor exchanged; 
however, the β-tubulin subunit accommodates both GTP and GDP at the E-site 
in an exchangeable and hydrolysable fashion (Stanton et al. 2011). MT 
polymerization occurs when free tubulin heterodimers containing a GTP molecule 
at the E-site of β-tubulin subunit integrates into the MT structure. The GTP 
molecule then undergoes hydrolysis and the resultant GDP remains bound to 
tubulin. During rapid growth of the MTs, new GTP bound subunits are added on 
to the MT polymer before the GTP of the previously added subunit has 
undergone hydrolysis, eventually leading to the build-up of GTP-containing 
tubulin subunits at the MT tip resulting in a “GTP cap.” However, during slow 
growth of MTs, there remains sufficient time for GTP to undergo the process of 
hydrolysis, which will then eventually lead to the exposure of a GDP-containing 
tubulin subunit at the tip of the MT. The hydrolysis of GTP reduces the binding 
ability of the neighbouring subunits, thus favouring the process of MT 
depolymerisation and a state of a curved configuration (Stanton et al. 2011). 
Therefore, straight protofilaments are acquired by GTP-containing tubulin, on the 
contrary to the curved protofilaments that are acquired by the GDP-containing 
ones (Warner & Satir 1973) (Figure 2). During “treadmilling,” which is another 
form of dynamic instability, tubulin dimers are constantly added to the plus-ends 
of the MTs which are simultaneously dissociated from the minus-end (Margolis & 
Wilson 1998; Margolis & Wilson 1978). 
 
  
 
 
 
 
 
Figure 2: Dynamic behaviour of MTs 
MT polymerization occurs when tubulin heterodimers containing a GTP molecule 
at the E-site of β-tubulin subunit integrates into the MT structure. GTP molecule 
then hydrolyses and GDP remains bound to tubulin. The GTP molecule that 
binds to the α-tubulin subunit via the N-site is neither hydrolyzed nor exchanged. 
During rapid growth of the MTs, new GTP-bound subunits are added on to the 
MT polymer before the GTP of the previously added subunit has not yet 
undergone hydrolysis, leading to a “GTP cap.” During slow growth of the MTs, 
GDP-containing tubulin subunit is exposed at the tip of the MT. This favours the 
process of MT depolymerisation and a state of a curved configuration. MTs are 
dynamic polymers that alternate between phases of growth and shortening with 
periods of undetectable activity or “paused” periods. This non-equilibrium and 
agitated behaviour is known as “dynamic instability.” The figure was adopted 
from Conde & Cáceres (2009).  
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GTP at the N-site of α-tubulin GDP at the E-site of β-tubulin 
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This process occurs during metaphase and anaphase, playing an important role 
in maintaining a constant length of the polymer while ensuring a constant flux of 
tubulin heterodimers from the plus-end to the minus-end of the MTs (McIntosh et 
al. 2002). Both dynamic instability and treadmilling are displayed simultaneously 
in some MTs, whereas in others they display one form or the other. However, the 
degree to which each of these behaviours is displayed relies largely on the ability 
of MTs to interact with MAPs, the expression of tubulin isotypes and their PTMs, 
such as phosphorylation, acetylation, polyglutamylation, polyglycylation or 
tyrosination/detyrosination (Farrell et al. 1987). In humans, there are 6 genes for 
α-tubulin and 7 for β-tubulin, and these isotopic forms are expressed differentially 
in different cells and tissues. PTMs further divide these isotypes into various 
subtypes, leading to differential overall efficacy to anti-tubulin drugs (Lewis et al. 
1985; Villasante et al. 1986; McKean et al. 2001). 
 
1.4 Microtubules and their binding partners 
MT dynamics are described by variables, such as the speed of MT growth and 
shortening and the rate of the transitions between “catastrophes” (rapid MT 
shrinkage) and “rescues” (switching back from shrinkage to growth). Regulation 
of these parameters occurs by the cellular expression of a group of modulating 
factors known as MAPs that fall into two major categories: MT-stabilizing and 
MT-destabilizing factors (Stanton et al. 2011). The stabilizing factors function by 
decreasing the speed of shortening, preventing catastrophes or by rescuing 
depolymerising MTs; on the contrary to the destabilizing factors enhance the 
speed of shortening and increase catastrophes.  
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Microtubule-stabilizing factors such as MAP1, MAP2, MAP4, tau and 
doublecortin (DCX) antagonises MT disassembly (Mollinedo & Gajate 2003; 
Drechsel et al. 1992). MAP4 is the most abundant and stabilizes MTs in non-
neuronal cells by specifically enhancing the rescue of depolymerizing MTs 
(Mandelkow & Mandelkow 1995). Previous reports suggest that cdk1 
phosphorylates MAP4 upon entry into mitosis, which causes a reduction of its 
binding efficiency to the microtubules and, hence, completely abrogates the MT 
stabilizing ability. This feature of MAP4 regulation suggests that this protein is 
specifically involved in stabilizing MTs at interphase. However, it is switched off 
during mitosis to ensure the dynamicity of MTs during the bipolar spindle 
formation (Vandré et al. 1991; Tombes et al. 1991). MT-plus-end-tracking 
proteins or +TIPs is a large group of MAPs that bind to the growing ends or the 
plus-ends of the MTs (Schuyler & Pellman 2001). Cytoplasmic linker proteins 
(CLIPs) are MT rescue factors that are found localized in the cytoplasm. The first 
member to be isolated was CLIP-170, which is localized to the plus-ends of the 
MTs in the form of small clusters (Rickard & Kreis 1990). CLIP-associated 
proteins, or the CLASPs, are dynamic MT stabilizing factors that are 
concentrated at different locations, such as the MT ends, the kinetochores or the 
centrosomes (Maiato et al. 2004). Their localization is also cell cycle dependent. 
For example, the CLASPs remain at the spindle midzone during anaphase and 
eventually migrate to the midbody matrix during telophase and cytokinesis, 
suggesting their role in the regulation of MT dynamics during mitosis (Lemos et 
al. 2000; Maiato et al. 2003). EB1 is another MT stabilizing factor that is involved 
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in overcoming MT catastrophe. Several reports suggest the involvement of EB1 
in MT associated functions such as cell division, morphogenesis and cell 
migration by interacting with other +TIPs (Vaughan 2005; Akhmanova & 
Steinmetz 2008).  
 
On the other hand, MT destabilizing factors induce MT depolymerisation and 
cause a reduction in their assembly by antagonising the activity of the stabilizing 
proteins (Maiato et al. 2004). Katanin, the first MT destabilizer to be discovered, 
causes MT severance by the energy liberated from MT-mediated ATPase activity 
(Vale 1991; McNally & Vale 1993; Hartman et al. 1998; Hartman & Vale 1999). 
Katanins are concentrated at the spindle poles and centrosomes in an MT-
dependent manner and play an important role in detecting defects in the 
microtubular lattice (Davis et al. 2002). The kinesin-13 family members, including 
Kif2A, 2B and 2C (mitotic centromere associated kinesin or MCAK) are MT 
depolymerizers that perform dual roles. Firstly, they induce catastrophe of the 
MTs through ATP hydrolysis and secondly sequesters tubulin in an ATP-
independent manner (Newton et al. 2004). Oncoprotein (Op) 18/stathmin is 
another MT destabilizing protein that is highly abundant in leukemic cells. 
Stathmin binds to tubulin via two binding sites to form a tubulin-stathmin 
complex, resulting in a kinked MT geometry. This induces a bent conformation in 
the MT lattice, thus, favouring MT disassembly and catastrophe (Jourdain et al. 
1997).  Stathmin is negatively regulated by cdk1 and polo-like kinase through 
phosphorylation. Hyper-phosphorylation and hence down-regulation of stathmin 
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was observed during mitosis to aid in the formation of the mitotic spindle 
(Marklund et al. 1996; Larsson et al. 1997).  
 
Motor proteins belong to a different category of MAPs and play a vital role in 
many of the MT functions, including cell division, that allows the sliding of MTs 
past each other and the transport of secretory vesicles and membrane bound 
organelles such as mitochondria and golgi bodies (Goldstein & Yang 2000). 
Kinesins and dyneins are the two major classes of motor proteins that depend on 
the MT network. Kinesins transport molecules towards the plus-end of the MTs 
with the help of the motor domain that generates energy via ATP hydrolysis and 
the tail domain that determine the cargo specificity. They play essential roles 
during cell division, particularly during spindle assembly and segregation of 
chromosomes and are also involved in transport (Goldstein & Philp 1999). 
Dyneins, on the other hand, are minus-end directing motor molecules composed 
of two or three heavy chains, with many distinct intermediate and light chains. 
They are essential for the transport of secretory vesicles and membrane bound 
organelles (Goldstein & Yang 2000). Therefore, kinesins and dyneins transport 
vesicles and organelles in opposite directions in an MT-dependent manner and 
are responsible for bi-directional intracellular transport. 
 
1.5 Mitosis 
Mitosis is a fundamental event that occurs during the life cycle of any proliferating 
somatic cell. When cells progress into mitosis, the dynamicity of the MTs is 
enhanced by approximately 20-100 times, in combination with a 7-fold increase 
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in the MT nucleation at the centrosomes (Saxton et al. 1984). The half-life of 
tubulin that is undergoing polymerization is very short during this period and 
remains only about 10-30 seconds in duration. When cells enter prophase and 
prometaphase, MTs grow rapidly in length and subsequently shrink in search of 
the kinetochores that need to be attached to the spindle MTs. As a result, each 
kinetochore of a chromosome is captured by MTs emanating from the opposite 
pole of the cell, resulting in a tensile alignment of the chromosomes at the 
metaphase plate. Anaphase begins only with the proper alignment of 
chromosomes, which will then eventually trigger the separation of chromatids 
towards opposite poles of the cell (Hayden et al. 1990; Piehl et al. 2004). This 
requires the rapid shrinkage of MTs attached to the kinetochores in combination 
with the assistance provided by the MT-associated motor proteins in 
chromosome separation (Maiato et al. 2004). Finally, during telophase, the 
chromosomes undergo decondensation to form two separate nuclei which are 
then followed by cytokinesis that requires the activity of the contractile actin-
myosin rings (Schmidt & Bastians 2007) (Figure 3). During the process of 
mitosis, proper chromosome alignment at the center plate is of utmost 
importance for the onset of anaphase and, hence, the faithful segregation of 
chromosomes to the newly formed two daughter cells. However, some cells fail 
to achieve the chromosome alignment and hence lead to chromosome instability 
and aneuploidy, which may eventually lead to cell death or tumorigenesis. 
 
  
 
 
 
 
 
 
Figure 3: The role of the mitotic spindle in mitosis 
During interphase, chromatin is not condensed and the MTs (green fibres) are 
distributed around the centrosome (orange circle) in a radial fashion. With the 
onset of prophase, chromosomes (blue) undergo condensation and duplicated 
centrosomes separate. The breakdown of nuclear envelope leads to 
prometaphase and the chromosomes are now not restrained in the nucleus 
(brown).  Kinetochore MTs (dark green) connect the kinetochores (red dot joining 
the chromatids) to the spindle MTs. This facilitates the alignment of 
chromosomes at the equator of the cell, leading to metaphase. The (-) ends of 
the MTs face the centrosome and the (+) ends face towards the cell equator. The 
(+) ends of the astral MTs emanating from the centrosomes, face the cell cortex. 
Early anaphase involves the movement of chromosomes towards the opposite 
poles of the cell, which is then soon followed by the late anaphase, where the 
spindle poles move apart. During telophase, chromosomes decondense and 
nuclear envelope is reformed. At the spindle midzone, a central bundle of MTs 
are present which aid in the process of cytokinesis and the faithful completion of 
the mitotic cell cycle. The figure was adopted from Walczak, Cai, & Khodjakov 
(2010). 
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To circumvent this potential problem, cells adopt a spindle assembly checkpoint 
(SAC) that inhibits anaphase onset until all the kinetochores are under tensile 
attachment to the spindle MTs. Therefore, in the presence of spindle poisons that 
interfere with the MT dynamics, many kinetochores may not get tensile 
attachment. This may trigger the activation of SAC, and cells are prevented from 
entry into anaphase, leading to a prolonged mitotic arrest (Schmidt & Bastians 
2007).  
 
1.6 Spindle activation checkpoint (SAC) 
Cells enter into mitosis with the activation of cyclin-dependent kinase 1 (cdk1) by 
its regulatory partner cyclin B. Once cells progress into metaphase, the exit of 
mitosis is governed by a SAC (Figure 4). During a normal mitotic cell division, 
SAC remains active only for a brief duration as the unattached kinetochores are 
rapidly picked up by the spindle MTs, correcting any improper attachments 
(Matson & Stukenberg 2011). When SAC is active, it inhibits the anaphase 
promoting complex or cyclosome (APC/C) activity, which is involved in the 
degradation of both cyclin B and securin (Clute & Pines 1999). This allows cdk1 
to be active and protects cohesin from degradation, thus delaying the onset of 
anaphase. Cell division cycle 20 (Cdc20) is essential for the ubiquitin ligase 
activity of the APC/C complex. When the SAC is active, core proteins of the 
checkpoint complex, including mitotic arrest deficient (Mad) 1, Mad2, budding 
uninhibited by benzimidazoles (Bub) 1, budding uninhibited by benzimidazole-
related 1 (BubR1) Bub3 and centromere protein (Cenp)-E interact with the 
kinetochores of the misaligned or unattached kinetochores.  
  
 
 
 
 
Figure 4: The role of the SAC in safeguarding against aneuploidy 
Bi-orientation of chromosomes ensures the accurate segregation of 
chromosomes to two daughter cells. Therefore, a tensile attachment between the 
kinetochores of the chromosomes and the MTs is essential to avoid 
missegregation and generation of aneuploidy.  In the presence of an unattached 
kinetochore (for example: during prometaphase), SAC is activated and the onset 
of anaphase is delayed until all the chromosomes are properly attached. Proteins 
of the SAC core complex, including Mad, Bub and Cenp-E proteins interact with 
the unattached kinetochore and a signal is generated to inhibit Cdc20-mediated 
activation of the APC/C. Cohesin protein that holds the sister chromatids 
together, is cleaved by separase during anaphase. However, the activity of 
separase is governed by at least the following two mechanisms: (1) The binding 
of securin to separase; and (2) interaction of cyclinB-cdk1 complex in a 
phosphorylation-dependent manner to separase, inhibits both cdk1 and 
separase. When chromosomes are properly attached, SAC is terminated, leading 
to the ubiquitination and degradation of both cyclin B (inactivation of cdk1) and 
securin and the initiation of anaphase. The figure was adopted from Holland & 
Cleveland (2009). 
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This generates a signal that abrogates the Cdc20-mediated activation of the 
APC/C and inhibit its ubiquitin ligase activity. However, when all of the 
chromosomes are properly attached, SAC is inactive and Cdc20 is now freely 
available to activate the APC/C complex. This leads to the degradation of cyclin 
B and securin and the completion of mitosis in a timely manner (Peters 2006). In 
the presence of microtubule-targeting agents or spindle poisons, the 
chromosomes will never be able to undergo a tensile attachment therefore, the 
SAC remains active for a longer duration that often lasts for hours. As a result, 
the cells will either undergo cell death during mitosis or exit mitosis aberrantly, by 
a phenomenon known as mitotic slippage (Brito & Rieder 2006).  
 
1.7 Microtubules as an epitome of anticancer targets 
A number of essential cellular functions including cell division, migration and 
intracellular transportation rely on the activity of the MT network along with their 
association with MAPs. Hence, MTs are undoubtedly recognised as validated 
targets for anti-cancer therapy (Jordan & Wilson 2004). Most of the MT-targeting 
drugs are involved in either promoting the assembly or the disassembly of the 
MTs by binding to tubulin directly or by altering the post- translational 
modifications associated with the MTs.  However, since the MTs are important 
entities for the normal functioning of non-cancerous tissues, anti-tubulin drugs 
have been reported to induce severe toxicities, including peripheral neuropathies, 
myelosuppression, immunosuppression and gastrointestinal toxicity. Therefore, 
continuous investigations are being carried out to establish novel drugs with a 
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better therapeutic index and minimal toxicities to surrounding non-cancerous 
tissues (Stanton et al. 2011).  
 
Most of the MT-binding drugs are either MT stabilizing agents (eg: taxanes, 
epothilones) or destabilizing agents (eg: vinca alkaloids, colchicine). However, 
the boundary between these two categories are sometimes not very clear as 
both the classes interfere with the dynamicity of MTs at nanomolar 
concentrations and, thus, they are collectively referred to as agents that suppress 
the dynamic instability of MTs (Jordan & Wilson 2004; Yvon et al. 1999; Panda et 
al. 1996).   
 
1.8 Microtubule Stabilizing Drugs (MSDs) 
MSDs bind to polymerized MTs and prevent their depolymerisation into individual 
α/β tubulin heterodimers. 
 
1.8.1 Agents binding to the taxane-binding site 
This group of microtubule stabilizing agents binds within the lumen of 
polymerized MTs, specifically at the β-tubulin subunit bound with GDP, and 
eventually, converts into a more stable GTP-bound conformation (Elie-Caille et 
al. 2007). This increases the rate of tubulin polymerization and hence the 
equilibrium is shifted from the soluble form of tubulin towards the polymerized 
form (Rao et al. 1999). Analogues of paclitaxel (Taxol®) and docetaxel 
(Taxotere®) along with other similar molecules bind to tubulin via the taxane-
binding site (Geney et al. 2005). The cytotoxic effects of these taxane-site 
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binding agents are attributed to their binding capacity to tubulin that leads to its 
stabilization and thus over-polymerization and, finally, leading to cell death by 
apoptosis (Morris & Fornier 2008).  
 
Taxoids: Paclitaxel (Figure 5), being the prototype of this group of drugs, is still 
regarded as the gold standard in the treatment of solid tumors, such as the 
carcinomas of the breast, ovary, prostate and lung. In the 1960s, paclitaxel was 
initially isolated from the barks of the Pacific Yew tree (Taxus brevifolia Nutt), 
which was then eventually approved by the FDA in 1992 as an ovarian cancer 
therapeutic (Stanton et al. 2011). Docetaxel, which is semi-synthetically 
synthesized from a precursor isolated from the European Yew tree (Taxus 
baccata L) was introduced as a second generation taxane with better 
pharmacological properties than paclitaxel. Docetaxel exhibited better water 
solubility and more activity against the proliferation of cancer cells, making it 
more useful in chemotherapeutic regimens for the treatment of breast and 
prostate cancers (Schmidt & Bastians 2007; Stanton et al. 2011). Tubulin 
polymerization by paclitaxel is favoured during all reaction conditions. The 
presence of low tubulin concentrations, reduced temperatures and absence of 
GTP or MAPs does not hinder its stabilizing activity (Kumar 1981; Thompson et 
al. 1981). Moreover, the presence of MT bundles not originating from the MTOC 
suggests that paclitaxel also facilitates its nucleation (De Brabander et al. 1981). 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Structures of Microtubule Stabilizing Drugs (MSDs) 
MSDs bind to tubulin, usually close to the taxane-binding site. This leads to the 
stabilization of the MT lattice that prevents MT depolymerisation and, eventually, 
lead to cell death (Stanton et al. 2011; Gerth et al. 1996; Liu et al. 2007; 
Giannakakou & Fojo 2000).  
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However, there are many factors that limit their use in a clinical setting, including 
acquired resistance, severe toxicities and hypersensitivity issues in the recipient 
patients (Stanton et al. 2011). Resistance to paclitaxel is acquired by at least two 
main causes. Firstly, the overexpression of P-glycoprotein (Pgp), which is 
responsible for the excessive efflux of paclitaxel from the tumor cells. Secondly, 
the overexpression of the βIII tubulin isoform that reduces paclitaxel’s binding 
ability to tubulin (Morris & Fornier 2008; Sève & Dumontet 2008). Paclitaxel is 
also associated with several dose-limiting side effects such as peripheral 
neuropathies and myelosuppression, making it difficult to use for a long-term 
clinical treatment. In addition, the reduced water solubility of paclitaxel requires 
its formulation with agents such as cremophor or DMSO leading to 
hypersensitivity in some patients. This suggests the urgent need to synthesise 
and characterize drugs which are more specific but highly efficient towards 
cancerous tissues (Stanton et al. 2011).  
 
Epothilones: Epothilones A and B (Figure 5) were originally produced using the 
myxobacterium, Sorangium cellulosum So ce90. These drugs belong to the 
family known as the macrolides (Gerth et al. 1996). These drugs bind close to the 
taxane-binding site as they were reported to show competitive binding with 
paclitaxel (Bollag et al. 1995). Since epothilones are generated using bacteria, 
they are easy to produce. Importantly, they are not transported via Pgp channels; 
hence, they can be used for the treatment of paclitaxel-resistant tumors 
(Kowalski et al. 1997). Two epothilones, patupilone and ixabepilone are currently 
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under development and clinical investigation, as they are more efficient and less 
toxic than paclitaxel. In addition, patupilone diffuse across the blood brain barrier 
whereas ixabepilone is effective against taxane-resistant tumors (Goodin et al. 
2004; Lee et al. 2001).     
 
1.8.2 Laulimalide and peloruside A 
Isolated from marine sponges, laulimalide and peloruside A (Figure 5) are 
effective against taxane-resistant tumors, similar to the epothilones. However, 
their use is limited due to their low therapeutic specificity. Previous studies using 
NMR suggested that laulimalide and peloruside A bind to tubulin through the α-
tubulin subunit. However, subsequent studies using mass spectrometry showed 
that these drugs bind to β-tubulin via a site adjacent to the taxane-binding site 
(Liu et al. 2007; Wilmes et al. 2007). Nevertheless, these drugs do not compete 
with paclitaxel in binding experiments and demonstrate synergistic behaviour 
with the taxanes, suggesting a combination regimen could be used to enhance 
their efficiency as chemotherapeutic agents (Hamel et al. 2006). 
 
1.8.3 Discodermolide and dictyostatin 
Both discodermolide and dictyostatin are similar to laulimalide and peloruside A, 
as they are derived from marine origin and exhibit synergistic effects with 
paclitaxel by binding to a different site on tubulin. Both of these agents are 
produced by marine sponges as a part of their defence mechanism and are 
involved in MT stabilization by increasing MT polymerization, and nucleation of 
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MT bundles, while decreasing MT depolymerisation (Madiraju et al. 2005; 
Giannakakou & Fojo 2000). 
 
1.9 Microtubule Destabilizing Drugs (MDDs) 
MDDs, at high concentrations lead to MT depolymerisation; however, both MSDs 
and MDDs are involved in disrupting the dynamicity of the MTs at low 
concentrations.   
 
1.9.1 Vinca-site binding agents 
Agents that compete with the binding of vinca alkaloids (eg: vinblastine, 
vincristine) to MTs are known as vinca-site binding agents (Chen et al. 2010). 
Vinca alkaloids, which were introduced into the clinics during the late 1950s and 
have proven to be successful. These agents are involved in MT destabilization by 
interfering with GTP hydrolysis and with nucleotide (GDP to GTP) exchange 
during the regeneration of  GTP-bound tubulins (Risinger et al. 2009).   
 
Vinca alkaloids: Isolated from Catharanthus roseus L commonly known as 
periwinkle, the vinca alkaloids (Figure 6) bind to the β-tubulin subunit close to the 
GTP-binding site. Hence, they interfere with the hydrolysis of GTP following 
tubulin polymerization and the nucleotide exchange of GDP with GTP (Cutts et 
al. 1960; Rai & Wolff 1996). This results in a curved or peeling conformation, 
unlike the straight or growing conformation that is preferred during MT growth 
and polymerization.  
 
  
 
 
 
 
 
 
 
 
 
 
Figure 6: Structures of Microtubule Destabilizing Drugs (MDDs) 
MDDs bind to tubulin and inhibit the polymerisation of the MTs at high 
concentrations and reduce the dynamic behaviour of the MTs at low 
concentrations. There are two main types of MDDs: (1) Vinca-site binding agents 
compete with the vinca alkaloids to bind to β-tubulin subunit, close to the GTP- 
binding site; and (2) Colchicine-site binding agents bind at the interface of α and 
β tubulin subunits, causing a conformational transition towards a curved tubulin 
geometry that favours MT depolymerisation.  
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These agents are also known as end poisons, as they bind to one or a few 
tubulin molecules at the plus-end of the MTs, preventing their copolymerization 
into the tubular lattice (Chen et al. 2010). At higher concentrations, the vinca 
alkaloids promote paracrystals, tubules and spirals formation by binding to free 
tubulin heterodimers (Takanari et al. 1990; Wilson et al. 1982; Warfield & Bouck 
1974). The first generation vinca alkaloids are vinblastine and vincristine; 
however, there are several semi-synthetic analogues including vinorelbine, 
vindesine and vinflunine (Risinger et al. 2009; Cutts et al. 1960) that are proven 
to be more effective than vinblastine. The parent compound and these agents 
are currently used for the treatment of lymphomas and leukemias (Kruczynski et 
al. 1998).  
 
Maytansinoids: This group of compounds are found in plants and include 
maytansine (Figure 6) (isolated from Maytenus ovatus Loes). Derived from 
Nocardia species, ansamitocin is a structurally similar compound to maytansine 
and is shown to possess antiproliferative property (Hamel 1996). Maytansinoids 
have been reported to exhibit 100-1,000 times better cytotoxic properties than 
vincristine or vinblastine  (Liu & Chari 1997). They inhibit the binding of vinca 
alkaloids, especially vincristine competitively; hence, they are thought to bind at 
least partially overlapping the vinblastine-binding site (Bai et al. 1993). However, 
dose-limiting side effects such as gastro and neuronal toxicities in combination 
with a low therapeutic value during the clinical trials discontinued further use as 
anticancer therapeutics (Cassady et al. 2004).  
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Vinca site-binding peptides: This group may include peptides, depsi-peptides, 
or cyclic or modified peptides that bind to tubulin at a site partially overlapping the 
binding site of the vinca alkaloids (Chen et al. 2010). Dolastatin analogues (from 
Dolabella auricularia Lightfoot) and cryptophycins (Figure 6) (from Nostoc, a 
cyanobacterium species) are well-characterized agents belonging to this group 
(Gupta & Bhattacharyya 2003; Hamel 1996). One of the most effective dolastatin 
analogues that binds to tubulin and causes a prominent mitotic arrest is 
dolastatin 10 (Figure 6).  It inhibits the binding of vincristine, rhizoxin and 
phomopsin A to tubulin and also prevents GTP hydrolysis and nucleotide 
exchange (R Bai, G R Pettit, et al. 1990a; R Bai, George R. Pettit, et al. 1990b; 
Ludueña et al. 1992). In spite of being a substrate of Pgp, dolastatin 10 is 
efficiently retained within tumor cells, leading to stronger inhibition of tumor cell 
growth as compared to clinically successful drugs such as vinblastine 
(Toppmeyer et al. 1994). Cryptophycins, on the other hand, are not  substrates of 
Pgp and show anticancer activity against multiple cancers (Smith et al. 1994). 
They inhibit vinblastine binding non-competitively and abrogate GTP hydrolysis 
(Smith & Zhang 1996). Cryptophycin-52 entered clinical trials but failed due to 
extreme toxicity profiles (Edelman 2003). 
 
Other vinca domain binding agents: Rhizoxin (Figure 6), which is a 
macrocyclic lactone is derived from Rhizopus chinensis Saito (Iwasaki et al. 
1984). It exhibits potent anticancer activity by binding at a site similar to 
maytansine, overlapping the vinblastine-binding site. Vinblastine, at high 
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concentrations promote the formation of tubulin aggregates, however this feature 
is not observed in the presence of rhizoxin (Takahashi et al. 1987; Gupta & 
Bhattacharyya 2003). Although rhizoxin is effective against human and murine 
cells along with their vincristine-resistant cell lines, clinical trial of rhizoxin was 
discontinued due to low efficacy (McLeod et al. 1996). Phomopsin A (from 
Phomopsis leptostomiformis Bubak) (Hamel 1996) and ustiloxins (from 
Ustilaginoidea virens Takahashi) (Koiso et al. 1994) arrest cells in mitosis by 
preventing the polymerization of MTs. In addition, similar to the vinca alkaloids, 
these two compounds also inhibit tubulin-dependent GTP hydrolysis, GDP-GTP 
nucleotide exchange and promote spiral aggregation of tubulin (R Bai, George R. 
Pettit, et al. 1990; Hamel 1996; Ludueña et al. 1990). However, they do not 
exhibit potent cytotoxic properties and require about 1,000 fold higher 
concentrations than paclitaxel and vinblastine to kill cells. Although the 
mechanism for this effect is not yet known, the permeability of the cell membrane 
and the rate of drug metabolism is thought to play a role (R Bai, G R Pettit, et al. 
1990; Koiso et al. 1994; Li et al. 1995). 
 
1.9.2 Colchicine-site binding agents  
The colchicine-binding site is situated at the interface of the α- and β-tubulin 
subunits. When colchicine binds to tubulin, a conformational transition occurs to 
yield a curved tubulin geometry, followed by the inclusion of the colchicine-tubulin 
complex within the protofilament. The steric clash that arises during this process 
favours the process of MT depolymerisation (Downing & Nogales 1999; Downing 
& Nogales 1998; Garland 1978). 
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Colchicine: Colchicum autumnale L, commonly known as meadow saffron, was 
used first to extract colchicine (Figure 6), the first MT destabilizing agent to be 
discovered (Peterson & Mitchison 2002; Zhou & Giannakakou 2005). Colchicine 
was then used to investigate detailed properties of the MTs and its subunits 
(Stanton et al. 2011). Colchicine binds to tubulin via a two-step process. Firstly, 
colchicine associates with tubulin reversibly and with low affinity to form a pre-
equilibrium complex, which then undergoes conformational changes that lead to 
the formation of a nearly irreversible tubulin-colchicine complex, favouring MT 
depolymerisation (Stanton et al. 2011). Similar to the vinca alkaloids, colchicine 
hinders the MT dynamics at low concentrations and reduces the MT polymer 
mass at high concentrations. Colchicine causes more toxicity in cancer cells due 
to their high rate of proliferation as compared to the normal cells; however, 
colchicine administration leads to severe dose-limiting side effects including 
neutropenia, myelosuppression, anemia and gastrointestinal toxicities that 
reduces its therapeutic value and limits its use as a safe anticancer agent (Lu et 
al. 2012).  
 
Combretastatins: Isolated from Combretum caffrum Kuntze, commonly known 
as the South African tree (Hamel 1996), combretastatins inhibit the 
polymerization of MTs via binding to tubulin at the colchicine-binding site. This 
causes a severe mitotic arrest in the treated cells that leads to cell death through 
apoptosis (Zhou & Giannakakou 2005; Hamel 1996). In terms of both cytotoxic 
properties and binding capacity, the most effective combretastatin is 
30 
 
combretastatin A4 (Figure 6), which is administered as a phosphate salt due to 
its poor solubility. It, then undergoes dephosphorylation to form the active 
product, combretastatin A4 in vivo (Lu et al. 2012).  
 
Combretastatins have been reported to block the vasculature within the core of 
the tumor by causing the endothelial cells that line the capillaries to swell up; 
however, the edge of the tumor remains unaffected, therefore, combinational 
regimens including drugs like paclitaxel are needed to kills cells at the tumor 
margins (Ahmed et al. 2003).  
 
There are several clinical trials using combretastatin A4 for multiple cancers, 
including relapsed ovarian cancer, anaplastic thyroid cancer and lung cancer. 
High blood pressure, being the major side effect during the treatment is kept 
under control using medications, nevertheless there are currently no 
combretastatin drugs approved by the FDA (Rustin et al. 2010).  
 
2-Methoxyestradiol (2-ME): It is an endogenous derivative of β-estradiol that is 
formed via a hydroxylation and a methylation reaction by enzymes, cytochrome 
P-450 and catechol O-methyl transferase, respectively. 2-ME (Figure 6) exhibits 
potent anti-proliferative ability and is known to inhibit tumor vasculature 
(Mabjeesh et al. 2003). In addition, 2-ME reduces the rate at which the MTs 
assemble by binding at the colchicine site (D’Amato et al. 1994). However, 
clinical studies show signs of several adverse effects including diarrhoea, fatigue, 
31 
 
nausea, neuropathy, dyspnea and edema (Matei et al. 2009). ENMD-1198 is a 
chemically derived analogue that exhibits better metabolic stability along with the 
ability to prevent proliferation of endothelial cells, migration, motility, 
morphogenesis and to damage the tumor vasculature within a short period of 
time (Bohlin & Rosén 1996; Pasquier et al. 2010).  
 
Podophyllotoxin: Isolated from the roots of Podophyllum peltatum L, 
podophyllotoxin (Figure 6) and its analogues are used in the treatment of several 
ailments including tuberculosis, gout, syphilis, rheumatism, cirrhosis, constipation 
and cancer (Desbène & Giorgi-Renault 2002). Podophyllotoxin has been 
reported to inhibit tubulin polymerization by binding to tubulin via the colchicine-
binding site, more rapidly and reversibly than colchicine (Lu et al. 2012; Stanton 
et al. 2011). Podophyllotoxin was employed as the lead compound to synthesize 
less toxic derivatives known as etoposide and teniposide. Both these compounds 
are used in combinatorial regimens where etoposide functions more effectively 
as a topoisomerase II inhibitor than a tubulin polymerization inhibitor (Desbène & 
Giorgi-Renault 2002; Hamel 1996).  
 
1.10 Importance of agents binding to colchicine site 
Tubulin binding chemotherapeutics such as the vinca alkaloids and taxanes have 
been immensely successful in the clinic, however colchicine-site binding agents 
have not yet entered a commercial phase. Although the use of colchicine as an 
anticancer agent is restrained due to its low therapeutic value, multiple efforts are 
undertaken to establish colchicine binding-site agents. As detailed above and in 
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a plethora of published data within the past few years, numerous agents that bind 
to the colchicine-binding site have been synthesized and characterized with the 
hope of developing a safe but efficient anticancer drug. Colchicine site-binding 
agents are particularly attractive due to several reasons. Firstly, they have the 
potential to serve as effective vascular disrupting agents and angiogenesis 
inhibitors. Secondly, their ability to overcome multidrug resistance (MDR) would 
enhance the intracellular drug concentrations. MDR arises due to the 
overexpression of the MDR1 gene that encodes Pgp and, as previously 
mentioned, both taxanes and vinca alkaloids are substrates of this drug efflux 
pump, leading to the reduction in cellular drug concentration and hence their 
cytotoxic potential. Apart from the overexpression of drug efflux pumps, 
resistance to drugs also arises due to mutations in tubulin that alters the binding 
sites of the drugs and secondly due to the overexpression of the βIII-tubulin 
isoform that leads to a considerable increase in MT dynamics (Lu et al. 2012).  
Previous reports suggest that the colchicine-site binding agents, including 
colchicine itself and 2-ME, are not affected by β-tubulin expression pattern 
(Mollinedo & Gajate 2003; Jordan et al. 1998). However, the major problems 
associated with this group of compounds are their reduced oral bioavailability 
and a reduced therapeutic index, apart from metabolic instabilities and poor 
pharmacokinetic profiles. Dose-limiting side effects, including peripheral 
neuropathies, myelosuppression and hypersensitivities discourage the use of 
these agents as main stream therapeutics. Therefore, research efforts are 
underway to establish novel colchicine-site binding agents with improved 
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therapeutic index. However, no agent binding to tubulin via the colchicine-binding 
site has thus far been approved as a valid anticancer therapeutic (Lu et al. 2012).      
 
1.11 Colchicine-site binding agents in clinical trials 
Colchicine has been employed in several clinical trials for the treatment of 
multiple diseases, including cancer; however, severe toxicities associated with 
the administration of colchicine forced to the discontinuation of its use as an 
anticancer therapeutic. ZD6126, a potent antiangiogenic and antineoplastic agent 
was examined for its potential in clinical trials for treating metastatic colorectal 
cancers; however, severe cardiotoxicity forced termination of the studies at the 
phase II stage (Goto et al. 2002; Lippert 2007). Zybrestat (combretastatin A4P), 
developed by OxiGene, is currently being evaluated for the treatment of recurrent 
ovarian cancer and neuroendocrine tumors. Multiple phase II clinical trials are 
either completed or ongoing for zebrestat for the treatment of solid tumors such 
as relapsing ovarian cancer, anaplastic thyroid cancer and non-small cell lung 
cancer (NSCLC) (Rustin et al. 2010). Oxi4503 (combretastatin A1 diphosphate) 
is employed mainly to target the tumor vasculature. However, currently, a phase I 
clinical trial is also being conducted for refractory acute myelogenous leukemia 
(AML) and myelodisplastic syndrome (MDS) (Lu et al. 2012). Ombrabulin 5 
(AVE8062) is a more water soluble and orally bioavailable analogue of 
combretastatin A4 that exhibits better anticancer properties with reduced 
toxicities in the Colon 26 (murine) carcinoma model. The antitumor activity of 
ombrabulin 5 is due to its ability to disrupt the formation of new blood vessels in 
tumors, and it has been reported to be effective against taxane-resistant cells 
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(Tae et al. 2007). During a phase I clinical trial, ombrabulin 5 was administered in 
combination with docetaxel and was well-tolerated by patients (Eskens et al. 
2014). Teniposide, asetoposide and etoposide phosphate are useful drugs that 
are synthesized from the lead compound podophyllotoxin (Bohlin & Rosén 1996). 
Both teniposide and etoposide are used in clinical settings to treat several types 
of cancers, including small cell lung cancer (SCLC), lymphomas and testicular 
cancer. Etoposide and teniposide were approved by the US FDA in 1983 and 
1993, respectively. Thereafter, to enhance the tolerability in receiving patients, 
etoposide was approved in the form of gelatin capsules in 1987 (You 2005). 
Etoposide and teniposide are usually used as a combinational therapy for the 
treatment of lung cancers, leukemias and testicular cancers. Unfortunately, they 
show several side effects including myelosuppression, nausea, vomiting, hair 
loss and hypersensitivities, necessitating the development of safer drugs (You 
2005). Nocodazole, a lead compound for the synthesis of novel colchicine-site 
binding agents, is a potent antimitotic drug that interferes with MT polymerization 
leading to a reversible and rapid mitotic arrest. However, the use of nocodazole 
in the clinic is limited due to the severe side effects, including myelosuppression, 
leukopenia, neutropenia and anemia.  Nevertheless, nocodazole has been useful 
as a reference compound to explore the process of mitosis (Lu et al. 2012). 
T138067 inhibits the polymerization of MTs by covalently binding to the Cys239 
residue of the β-tubulin subunit. It was shown to be effective against tumors with 
multi-drug resistance phenotype; hence, T138067 entered phase II clinical trials. 
Unfortunately, it also showed signs of gastrointestinal, hematological and 
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neurotoxicities (Shan et al. 1999). Similarly, there are several other colchicine 
binding-site agents that have reached the clinical trials stage, including ABT-751 
(phase II), CI-980 (phase II), MN-029 (phase I). However, all of them are 
associated with several toxicities such as constipation, fatigue and abdominal 
pain for ABT-751(Hande et al. 2006), significant neurotoxicity for CI-980 (Thomas 
et al. 2002), and anorexia, diarrhoea, fatigue, nausea, vomiting and headache for 
MN-029 (Shi & Siemann 2005; Ricart et al. 2011). Therefore, despite their 
significant ability to arrest cell cycle progress and kill cancer cells through both 
mitotic and apoptotic pathways, severe dose-limiting side effects including 
neurotoxicity, thromboembolic and cardiovascular events warrant for continuous 
research on this group of agents to develop a safe and effective anticancer 
therapeutic in the near future.  
 
1.12 Summary of work presented in this thesis 
MTAs still remain one of the most successful antimitotics used for the treatment 
of cancer. Unfortunately, the inherent toxicities, hypersensitivities and acquired 
resistance to these drugs reduces their therapeutic index and, thus, warrants the 
development of better chemotherapeutic agents (Lu et al. 2012). This thesis 
provides evidence of novel chalcone derivatives that potentially fit this 
description. CTR compounds inhibit the proliferation of a broad range of cancer 
cells, at sub-micromolar concentration. I initially focussed on the characterization 
of CTR-17, and later I also studied the mechanism of action of CTR-20. The 
cytotoxic effects of CTR-17 and CTR-20 in cancer cells are 10-25 times more 
effective than non-cancer cells, which is a highly desirable property of anti-cancer 
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agents to achieve a better therapeutic index. When compared with colchicine that 
exerts only about 2.5 to 3.5 times better selectivity, for cancer cell killing over 
non-cancerous cells, CTR-17 and CTR-20 appear to be much more desirable 
drugs. CTR-17 arrests the cells in mitosis via the activation of the spindle 
checkpoint, thereby delaying mitotic exit by the inhibition of anaphase-promoting 
complex/cyclosome (APC/C) ubiquitin ligase activity. CTR-17 causes a 
prolonged mitotic arrest that lasts more than 20 hours in a variety of cell lines, 
including in HeLa, Hek293T, MDA-MB468 and MDA-MB231 cells. All these cells 
then eventually undergo cell death. However, in non-cancer cells (184B5 and 
MCF10A), only about 25% of cells undergo cell death and the remaining cells 
follow a normal cell cycle progression. 
  
Data from immunofluorescence staining experiments revealed that CTR-17 leads 
to elongation and denser astral MTs, defects in chromosome alignments, short 
spindles and fragmentation of centrosomal materials. Most of these effects are 
attributable to the inhibition of MT dynamics during mitosis and reduction of the 
MT polymer mass. Therefore, the ability of the CTR compounds, to inhibit MT 
polymerization was analysed using purified tubulin and cell culture systems. 
Fluorescence microscopy and molecular docking studies identified that both of 
the CTR compounds bind directly to tubulin partially overlapping the colchicine-
binding site. Importantly, both the CTR compounds were also effective against 
cells resistant to paclitaxel, vinblastine and colchicine.  
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In conclusion, data presented in this thesis suggests that novel chalcone 
derivatives, CTR-17 and CTR-20 have a broad range of anti-tumor activities via 
MT depolymerisation through its binding to tubulin at the colchicine-binding site. 
It is important to recognise that CTR-17 and CTR-20 exert lesser toxicity to 
normal tissues and are also active against cell lines resistant to drugs. These 
desirable properties identify CTR-17 and CTR-20 to be attractive lead 
compounds to design safer and more effective anticancer therapeutics. 
  
 
 
 
 
 
 
 
 
2.0 Materials and Methods 
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2.1 Cell culture  
All cancer cell lines were purchased from American Type Culture Collection 
(ATCC) (Manassas, VA) and cultured in Roswell Park Memorial Institute-1640 
(RPMI-1640) medium supplemented with 10% v/v fetal bovine serum (FBS) and 
1% v/v antibiotic antimycotic solution (100 units of penicillin, 100 μg of 
streptomycin, and 0.25 μg of amphotericin B per ml), purchased from Hyclone 
(South Logan, UT). 184B5 and MCF10A were cultured in Dulbecco's Modified 
Eagle's Medium/Ham's Nutrient Mixture F-12 (DME/F12) medium (HyClone) 
supplemented with 10% v/v FBS, 1% v/v antibiotic antimycotic solution,  0.5 
µg/ml hydrocortisone, 10 ng/ml human epidermal growth factor (hEGF) and 5 
µg/ml insulin (SingleQuots Kit, Clonetics, Burlington, ON, Canada).  
 
KB-3-1, the parental wild-type human epidermal cervical carcinoma cell line and 
KB-C2 which is an ABCB1/Pgp-overexpressing drug-resistant cell line were 
kindly provided by Dr. Amit K Tiwari (University of Toledo, OH). The KB-C2 cell 
line was established in the presence of increasing concentrations of colchicine by 
Dr. Shin-ichi Akiyama, Kagoshima University, Japan. The MRP-overexpressing 
cell lines, H69AR and the parental wild-type small cell lung carcinoma H69, was 
purchased from ATCC. H69AR cells were established in the presence of 
increasing concentrations of adriamycin (doxorubicin) by Dr. Susan Cole 
(Queen’s University Cancer Research Institute, Kingston, Canada). H69 cells 
grow as large multi-cell aggregates; hence, accurate cell counts were difficult. 
Therefore, cytotoxicity results obtained from H69AR cells were compared to 
SW1271 cells which are another small cell lung carcinoma cell line, purchased 
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from ATCC. All cells were maintained in a humidified incubator at 37°C with 5% 
CO2. Cell line authentication was performed through Genetica DNA Laboratories 
(Burlington, NC) using short tandem-repeat (STR) profiling (March 2015; July 
2015). 
 
2.2 Sulforhodamine B (SRB) assay 
An optimum density of cells (40,000/ml) was seeded in each well of a 96-well 
plate and incubated for 16 h as described previously (Vichai & Kirtikara 2006; 
Skehan et al. 1990). The medium was then replaced with different concentrations 
of the drugs dissolved in DMSO (final concentration of DMSO was 0.1%). Sham-
control wells contained only medium with DMSO (final concentration of DMSO 
was 0.1%). 100 µl of 10% trichloroacetic acid (TCA) was used as negative 
control (Thermo Fisher Scientific, Ottawa, ON, Canada). Incubation of cells with 
these agents was continued for an additional 72 h. The cells were subsequently 
fixed with cold 10% TCA for 1 h at 4ºC. TCA was then removed and cells were 
washed with cold tap water, and the plate was air-dried. Cells were then stained 
using 50 µl of 0.4% SRB (Sigma, Oakville, ON, Canada) in 1% acetic acid 
(Thermo Fisher Scientific) solution for 30 min. The unbound dye was washed off 
quickly with 1 % v/v acetic acid once followed by three washes with cold tap 
water. The plates were allowed to air dry and the bound SRB was then 
solubilised in 200 µl of 10 mM Tris Base, pH 10.5 (Thermo Fisher Scientific).  
Absorbance was measured at 540 nm using an automated plate reader (Synergy 
H4 Hybrid Multi-Mode Microplate Reader - Bio-Tek, Winooski, VT). Cell growth 
was calculated by the following formula: 
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% cells proliferation = [(A treated – A negative)/ (A sham – A negative)] x 100 
Where, A treated: absorbance of treated cells, A negative: absorbance of negative 
control cells, A sham: absorbance of sham treated cells. IC50 values were 
calculated from sigmoidal dose-response curves generated by at least two 
independent biological replicates, with quadruple technical replicates for each set 
using GraphPad Prism v.5.04 software (GraphPad Software, Inc, La Jolla, CA). 
For combinational experiments on the KB-C2 cell line, CTR compounds and 
paclitaxel were used in six different ratios; namely, 0.5IC50:0.5IC50, 0.5IC50:IC50, 
IC50:IC50, IC50:0.5IC50, IC50:0.25IC50 and IC50:0.125IC50. The combination index 
(CI) was calculated using the following formula (Chou 2006). 
 
 
 
Where, D: Dose of the drug, Dm: Median effect dose, Fa: Fraction affected, m: 
slope of the curve. If the CI values were less than, equal to or more than 1, it 
indicated a synergistic, additive or antagonistic effect, respectively (Chou 2006). 
CI values were determined from four independent experiments.  
 
2.3 Synchronization of cells 
HeLa cells were synchronized at the G1/S border of the cell cycle using a double 
thymidine block as described previously (Romero & Lee 2008). Briefly, the cells 
were exposed to 2.0 mM thymidine (Sigma) for 18 h and subsequently washed 
with 1X PBS (2.7 mM KCl, 1.0 mM KH2PO4, 137 mM NaCl, 10 mM NaH2PO4, pH 
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7.5). Cells were then maintained in drug-free medium for 11 h followed by a 
second thymidine exposure for 14 h. The cells were then washed again with 1X 
PBS and released into complete medium in the absence (sham) or presence of 
3.0 μM CTR-17 for different durations.  
 
2.4 Cell cycle analysis by flow cytometry  
Cell cycle analysis by flow cytometry using propidium iodide was carried out as 
described previously (Solomon et al. 2009). Exponentially growing cells treated 
with different concentrations of CTR-17 were harvested using a cell scraper at 
the scheduled time points. Cell pellets were collected by centrifugation at 1,100 
rpm (AllegraTM X-12 centrifuge, Beckman Coulter, Mississauga, ON, Canada) 
for 5 min. The cells were then washed once with 1X PBS and fixed with 75% 
ethanol at -20°C for 18 h. Cells were then washed twice, with 1X PBS to remove 
ethanol by centrifugation at 1,100 rpm (AllegraTM X-12 centrifuge) for 5 min. 
Cells were then stained with propidium iodide (Life Technologies, Burlington, ON, 
Canada) solution (PI) for 1 h, protected from light. The PI solution contained 
0.1% v/v PBS, 0.3% v/v Nonidet P-40, 100 µg/ml RNase A and 100 µg/ml 
propidium iodide. Samples were then analyzed using a Beckman Coulter Epics 
Elite FC 500 Flow Cytometer (Mississauga, ON, Canada). The forward 
scatter/side scatter (FS/SS) plot was used to exclude potential doublets and 
debris were excluded during the analysis of the total counts. To determine if the 
activity of the compounds were reversible, HeLa cells were treated for 12 h with 
CTR-17 or CTR-20. The floating cells were collected by centrifugation at 1,100 
rpm (AllegraTM X-12 centrifuge), washed twice with 1X PBS and released into 
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fresh culture medium. The adherent cells were washed with 1X PBS and fresh 
medium was also added to these plates. At scheduled time points, both the 
populations of cells (adherent and floating) were harvested as previously 
explained, prior to performing flow cytometry. Data were generated from at least 
three biological replicates. 
 
2.5 Immunofluorescence staining 
Cells were plated on coverslips placed in 35 mm tissue culture plates or 6-well 
cluster dishes, and allowed to adhere overnight. Immunofluorescence staining 
was carried out as described previously (Santi & Lee 2011). Cells were then 
either sham-treated or treated with CTR-17 or CTR-20 for scheduled durations. 
Subsequently, the cells were fixed with 100% methanol for 15 min at -20°C and 
washed with 1X PBS thrice. The cells were then blocked with PBST (1X PBS and 
0.1% v/v Triton X-100) supplemented with 1% v/v FBS for about 1 h and 
incubated overnight at 4°C in a PBST solution containing primary antibody. In the 
case of double staining, a mixture of antibodies was added in equal ratio with 
gentle agitation. Unbound antibodies were washed off with PBST (3X) and 
secondary antibody solution was added and incubated for 1 h, in protection from 
light. The secondary antibody solution contained Alexa488 and Alexa568 
conjugated antibodies (Life Technologies). Draq 5 or Dapi was used to stain 
nuclei.  Subsequently, the coverslips were washed thrice using PBST for 10 min 
each and mounted onto slides with 90% glycerol in 1X PBS. Each slide was 
visualized with a Carl Zeiss 510 Meta laser scanning microscope or axioscope, 
and analysis was done with LSM image examiner (Carl Zeiss, North York, ON, 
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Canada).  For each staining experiment, a background control (without 
secondary antibody) and bleed-through controls (cells labeled with each 
fluorophore separately) were used to avoid any potential bleed-through artifacts. 
A minimum of 10 fields per coverslip or 200 cells were captured for every sample 
and each experiment was repeated at least twice. 
 
2.6 EdU labeling  
To examine the effect of CTR-17 on DNA synthesis, EdU labeling was performed 
as described previously (Salic & Mitchison 2008). The DTP analogue EdU (5-
ethynyl-2′-deoxyuridine) was added, and its incorporation into DNA was detected 
using a Cu (I)-catalyzed cycloaddition reaction with a fluorescent azide. Cells that 
were allowed to adhere overnight on coverslips in 35 mm tissue culture plates 
were either sham-treated or treated with CTR-17 for 24 h. During the final 1 h, 
10.0 µM EdU (Life Technologies) was added to cell culture in dark at 37°C with 
5% CO2. EdU-labeled cells were then fixed with 4% formaldehyde for 15 min at 
room temperature and were rinsed with TBS (40 mM Tris pH 8.05, 150 mM 
NaCl) three times, 10 min each. The cells were then stained in a freshly-made 
staining solution containing 100 mM Tris, pH 8.5, 1 mM CuSO4, 1 µg/ml 
Alexa546-azide (Active Motif through Cedarlane) and 100 mM ascorbic acid 
(added last to the staining mixture) for 30 min in dark at 22°C with gentle 
shaking. The cells were subsequently washed several times (or sometimes 
overnight) with TBS and counterstained with Draq 5. Coverslips were then 
mounted and visualized as described previously. The results were generated 
from three biological replicates. 
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2.7 Live cell imaging 
About 10,000 Hek293T cells were plated in each 35 mm tissue culture plate and 
allowed to adhere overnight. The cells were then transfected for 16 h with 3.0 µl 
of CellLight Tubulin-GFP (C10613, Life Technologies) to label the microtubules, 
according to the manufacturer’s instructions. It is a fusion construct of human 
tubulin and emGFP in a baculovirus vector. Each CellLight® reagent has 1 × 108 
particles/ml, and for efficient transfection, it was ensured that each cell received 
an average of 30 of these particles. The medium was then replaced with a 
FluoroBrite™ DMEM (Life Technologies) with or without CTR-17, and 
immediately visualised by live cell microscopy (IX73 inverted microscope-
Olympus, Toronto, ON, Canada). Time-lapse fluorescence images were obtained 
for 24 h at 5 min intervals. The live cell imaging was performed at least in two 
biological replicates for individual samples. 
 
2.8 Western blotting 
Western blot analysis was performed as described previously (Santi & Lee 
2010). Exponentially growing cells were treated with CTR-17 or CTR-20 and 
collected at scheduled time points using a cell scraper. Cells were centrifuged at 
1,100 rpm (AllegraTM X-12 centrifuge) and then washed once with 1X PBS and 
lysed on ice for 10 min using lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 
1 mM EDTA and 1% (v/v) Triton X-100, supplemented with 1 mM 
phenylmethylsulfonyl fluoride (PMSF), 5 mM protease inhibitor and 5 mM 
dithiothreitol just before use). The lysates were cleared by centrifugation at 
10,000 rpm for 10 min at 4ºC (Microfuge 22R centrifuge, Beckman Coulter) and 
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the protein concentration in the supernatant was determined using a BCA 
(Bicinchoninic acid) assay (Pierce, Thermo Fisher Scientific). The protein 
extracts were then diluted with 5X SDS-PAGE loading buffer (312.5 mM Tris-
HCl, pH 6.8, 10% v/v glycerol, 11.5% v/v sodium dodecyl sulphate (SDS), 0.05% 
w/v bromophenol blue, 5% β-mercaptoethanol) and equal amounts of proteins 
(25-40 µg/ml) were loaded onto 6-15% polyacrylamide gels. Proteins were 
separated by electrophoresis using Tris-glycine running buffer (25 mM Tris, 192 
mM glycine, 0.1% w/v SDS) at 90-120V for 2 h. On the completion of 
electrophoresis, the proteins were transferred to nitrocellulose or polyvinylidene 
fluoride (PVDF) membranes (Amersham Biosciences through Cedarlane) using a 
semi-dry transfer system (Bio-Rad, Mississauga, ON, Canada) and protein 
transfer buffer (50 mM Tris, 40 mM glycine, 0.04% w/v SDS, 20% v/v methanol) 
at 25 V for 1 h. The membranes were then blocked for 45 min in a blocking 
solution containing TBS and 5% w/v skim milk powder (Carnation®). The 
membranes were then incubated overnight at 4°C with different antibodies 
diluted in TBS with 5% w/v skim milk powder or TBS with 5% w/v bovine serum 
albumin (BSA), when detecting phosphorylated proteins. The membrane was 
then washed three times with TBST (TBS with 0.05% Tween-20) and incubated 
for 1 h in a solution containing horseradish peroxidase (HRP)-conjugated 
secondary antibody in TBST and 5% w/v skim milk powder. The membranes 
were washed again three times in TBST and the immunoreactivity was visualized 
using X-ray film exposure and enhanced chemiluminescence (ECL) western blot 
reagents (Amersham Biosciences).  
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2.9 Immunoprecipitation 
Immunoprecipitation was performed as described previously (Kim & Lee 2008). 
Synchronised cells following double thymidine treatment were either sham 
treated or treated with the indicated drugs for scheduled durations. Cell lysates 
were prepared in 1X IP buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM 
EDTA and 1% (v/v) Triton X-100, supplemented with 10 mM sodium fluoride, 1 
mM sodium orthovanadate and 5 mM cocktail of protease inhibitors), and then 
pre-cleared for 3 h using 50 µl of protein A/G agarose beads, sc-2003 (Santa 
Cruz Biotechnology, Dallas, TX) at 4°C with gentle agitation. Subsequently, 
immunoprecipitation was performed with 5.0 µg of a rabbit polyclonal anti-BuBR1 
antibody (Table A1, page 147), or 5.0 µg of a rabbit polyclonal normal IgG (Table 
A1) as negative control.  50 µl of protein A/G beads were added for an additional 
5 h at 4°C (gentle agitation) and centrifuged at 2,500 rpm for 5 min at 4ºC 
(Microfuge 22R centrifuge) to recover these immunocomplexes. They were then 
subsequently washed five times in IP lysis buffer and boiled for 5 min prior to 
SDS-PAGE and Western blotting. Cdc20 was detected using a rabbit polyclonal 
anti-cdc20 antibody (Table A1). Data were generated from at least two biological 
replicates. 
 
2.10 Microtubule assays 
2.10.1 Microtubule polymerization assay 
The effects of CTR compounds on the ability to assemble purified tubulin were 
determined using a tubulin polymerization kit (BK004P, Cytoskeleton Inc. through 
Cedarlane) according to the manufacturer’s instructions.  Each reaction mixture 
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contained 4.0 mg/ml of porcine tubulin in G-PEM buffer (1.0 mM guanosine 
triphosphate (GTP), 80 mM piperazine-N,N'-bis[2-ethanesulfonic acid] 
sequisodium salt (PIPES), pH 6.9, 0.5 mM ethylene glycol-bis(2-
aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA) and 2.0 mM MgCl2), 
supplemented with 10 % glycerol. 10.0 µM of paclitaxel which is an MT stabilizer 
(provided in the same assay kit), 5.0 µM of nocodazole, an MT destabilizer (sc-
3518; Santa Cruz Biotechnology) and G-PEM buffer without drugs were used as 
controls for the assay. The assay kit is based on the principle that the light 
scattered by the microtubules is directly proportional to the polymer mass of the 
microtubules when measured at 37°C at 340 nm. Absorbance was measured 
using an automated plate reader (Synergy H4 Hybrid Multi-Mode Microplate 
Reader) for 1 h at 1 min interval. The experiment was performed in three 
biological replicates. 
 
2.10.2 Differential tubulin extraction  
A two-step extraction procedure, as described was used to differentially extract 
tubulin heterodimers and microtubules from sham or treated cells (Tokési et al. 
2010). Exponentially growing cells were treated with 50 nM of paclitaxel, 50 
ng/ml nocodazole, 3.0 µM of CTR-17 or 1.0 µM of CTR-20 for 12 h. The cells 
were then harvested and lysed with a pre-warmed microtubule stabilizing buffer 
(80 mM PIPES, pH 6.8, 1mM MgCl2, 1 mM EGTA, 0.5% Triton X-100, 10% 
glycerol, and 5.0 mM protease inhibitor cocktail). The lysate was then centrifuged 
at 2,500 rpm for 5 min at room temperature (Sorvall™ Legend™ Micro 17 
centrifuge, Thermo Scientific). The supernatant containing the soluble tubulin 
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heterodimers was transferred to fresh tubes. To ensure that the soluble tubulin 
was completely extracted, the cell pellet was washed once again with the 
microtubule stabilizing buffer and the supernatants were pooled to form the 
soluble tubulin fraction. The polymerized tubulin fraction was then extracted from 
the cell pellet in microtubule destabilizing buffer (20 mM Tris, pH 7.4, 150 mM 
NaCl, 1% Triton X-100, 10 mM CaCl2, and 5.0 mM protease inhibitor cocktail). 
The extract was cleared by centrifugation at 2,500 rpm for 5 min at room 
temperature (Sorvall™ Legend™ Micro 17 centrifuge) to obtain the insoluble 
microtubule fraction. An equal volume of both the soluble and polymerized 
fractions and 40 µg of protein for sham-treated and treated samples as 
determined by a BCA assay were resolved by SDS-PAGE. The resultant 
Western blot was analysed by densitometry using AlphaEaseFC 4.0 software 
(Alpha Innotech Corp. San Leandro, CA). The experiment was performed in three 
biological replicates. 
 
2.10.3 Determination of the dissociation constant using tryptophan 
fluorescence of tubulin 
Intrinsic tryptophan fluorescence was used to determine the binding constants of 
CTR-17 and CTR-20 as reported previously (Rai et al. 2012). Purified porcine 
tubulin (T240) was purchased from Cytoskeleton Inc. 0.4 µM of tubulin was 
dissolved in 25 mM PIPES buffer, pH 6.8, and incubated in the absence or 
presence of different concentrations of compounds for 30 min at 37°C.  The 
intrinsic fluorescence of tryptophan residues in the tubulin heterodimers was 
monitored by excitation at 295 nm and the emission spectra were recorded from 
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315-370 nm. All measurements were corrected for the inner filter using the 
formula Fcorrected = Fobserved X antilog [(Aex+Aem)/2], where Aex and Aem are the 
absorbance of the reaction mixture at the excitation and emission wavelengths, 
respectively. GraphPad Prism software was used to determine the dissociation 
constants of CTR-17 and CTR-20 binding to tubulin using the following formula:  
 
Where, ∆F is the change in fluorescence intensity of tubulin when bound to CTR 
compounds, ∆Fmax is the maximum change in the fluorescence intensity when 
tubulin is bound with the drugs, C is the concentration of CTR-17/CTR-20, and Kd 
is the dissociation constant of CTR-17 or CTR-20. The experiment was 
performed in five biological replicates. 
 
2.10.4 Competitive binding assay 
Competition binding assays were performed as shown previously (Rai et al. 
2012). For BODIPY® FL Vinblastine competition assay, 25.0 µM of CTR-17, 
CTR-20, colchicine, C9754 (Sigma), vinblastine, ab141475 (Abcam) was 
incubated with 0.4 µM purified tubulin for 1 h at 37°C. Subsequently, BODIPY® 
FL Vinblastine, V12390 (Life Technologies) was added to the tubulin complexes 
to a final concentration of 5.0 µM, and incubated further for 30 min at the same 
temperature. For the colchicine competition assay, tubulin (0.4 µM) was 
incubated with different concentrations of CTR-17, CTR-20 or vinblastine for 1 h 
at 37°C. Subsequently, colchicine was added to the CTR-17/CTR-20-tubulin or 
vinblastine-tubulin complexes. To determine the inhibition constant (Ki), 
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colchicine was added to a final concentration of 3.0 µM, 5.0 µM or 8.0 µM to 
different concentrations of CTR-17-tubulin complexes, and 1.0 µM, 3.0 µM, 5.0 
µM and 8.0 µM to different concentrations of CTR-20-tubulin complexes. 
Fluorescence was monitored using an automated plate reader (Synergy H4 
Hybrid Multi-Mode Micro plate Reader). For the vinblastine competition assay, 
fluorescence was monitored by excitation at 490 nm and the emission spectra 
were recorded at 510-550 nm. For the colchicine competition assay, the 
fluorescence of the tubulin complexes was determined with an excitation 
wavelength of 360 nm and emission wavelength at 430 nm. A modified Dixon 
plot was used to analyze the competitive inhibition of colchicine binding to tubulin 
and to determine the Ki of CTR-17 and CTR-20. The experiment was performed 
in four biological replicates. 
 
2.11 Molecular docking  
Molecular Operating Environment (MOE) (Chemical Computing Group Inc, 
Montreal, Quebec, Canada) was used to predict the interaction model of CTR-17 
and CTR-20 binding to the colchicine binding domain of the β-tubulin subunit. 
The crystal structure of the tubulin-colchicine complex (PDB Code: 1SA0) was 
used as the target structure and was subjected to energy minimization and 
protonation via the same software. The protocol for docking was adopted from 
that posted to the MOE website and an induced-fit protocol was used 
(http://www.chemcomp.com/ MOE-Structure_Based_Design.htm). CTR-17 and 
CTR-20 were docked close to the colchicine-binding site and the best docking 
pose was determined based on the minimum free energy for binding. The 
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contributions of hydrogen bonds, hydrophobic, ionic and Van der Waals 
interactions were taken into consideration when calculating the free energy of 
binding.  
 
2.12 Scratch-wound healing assay 
A scratch-wound healing assay (Liang et al. 2007) was used to measure the 
migration of cells in vitro in the presence or absence of CTR-17 in a time-
dependent manner. Human MDA-MB231 cells were plated to 90% confluency to 
obtain a monolayer on a 35 mm tissue culture dish. After the cells were allowed 
to adhere overnight, a scratch was made in a straight line using a p200 pipette tip 
and the cells were then washed once with 1XPBS. To completely remove any 
debris, the monolayer was washed two more times with regular media. The cells 
were then either sham-treated or treated with CTR-17 and immediately subjected 
to time-lapse imaging for 72 h with an IX73 inverted microscope. The percentage 
of wound closure was then quantified using ImageJ software, which is an open 
access software, developed by the National Institute of Health 
(rsb.info.nih.gov/ij). The experiment was conducted in three biological replicates. 
 
2.13 Estimation of doubling time in cancer vs non-cancer cells 
The doubling time of the cancer vs non-cancer cells was used to determine if the 
cancer cell specificity of the CTR compounds was due to the difference in the 
doubling time of cancer vs non-cancer cells. Two different approaches were used 
to estimate the doubling time of HeLa, MDA-MB231, MDA-MB468, Hek293T, 
184B5 and MCF10A.  
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Approximately, 15,000 cells/ml were plated in a 35 mm dish (trypan blue 
exclusion assay) or a 24-well culture plate (SRB assay). For a trypan blue 
exclusion assay (Strober 2001), the cells were trypsinised and the cell pellets 
were collected by centrifugation at 1,100 rpm (AllegraTM X-12 centrifuge) for 5 
min. Cell pellets were then re-suspended in 1.0 ml of culture medium. An aliquot 
was mixed in an equal volume of 0.4% Trypan blue solution (Sigma). For SRB 
assay, the cells were fixed and stained as outlined in section 2.2. Both the 
assays were conducted for eight consecutive days and the growth curves were 
constructed using Microsoft excel. The log phase of the curve was used to 
determine the doubling time of each cell line. Doubling times were determined 
using trypan blue exclusion assay, conducted once and SRB assay which was 
performed in two independent replicates.   
 
2.14 CTR cell permeability test 
The intracellular concentration of the CTR compounds in cancer vs non-cancer 
cells was determined by high performance liquid chromatography (HPLC) 
method as previously described with minor modifications (Ren & Wei 2004; Jorfi 
et al. 2015). Cells were either sham-treated or treated with 3.0 µM of CTR-17 for 
scheduled time points. The medium was removed and the cells were washed 
twice with 1X PBS. The cells were then harvested using a cell scraper and cell 
pellets were collected by centrifugation at 1,100 rpm (AllegraTM X-12 centrifuge) 
for 5 min. The pellets were then re-suspended in 200 µl lysis buffer (20 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA and 1% (v/v) Triton X-100). The extract 
was sonicated for 2 min on ice using a sonic dismembrator, model 100 (Thermo 
54 
 
Fisher Scientific). 100 µl of acetonitrile (Thermo Fisher Scientific) was added to 
the extract, followed by centrifugation for 10 min at 17,000 x g (Sorvall™ 
Legend™ Micro 17 centrifuge) to remove proteins. The protein precipitation 
process was repeated again. The supernatant was collected in fresh tubes, 
filtered using Target2 Nylon Syringe Filters, F2504-2 prior to performing HPLC: 
pore sizes of the filters were 2.0 µm and the diameters were 4.0 mm (Thermo 
Fisher Scientific). The HPLC system consisted of a Shimadzu LC20AB pump 
(Laval, QC, Canada), equipped with an autosampler and a diode array detector. 
An injection volume of 5.0 µl of CTR-17 was introduced into a Restek LC column; 
Ultra C18 column (4.6 mm X 150 mm, 3.0 µm) and the absorbance of the 
samples were monitored at 350 nm. The system was run in an isocratic mode 
with a mobile phase containing methanol to water at a ratio of 70:30 (v/v). The 
flow rate used was 0.75 ml/min. The experiment was performed in two biological 
replicates.  
 
2.15 Assessment of combination effects using CTR compounds and X-ray 
radiation 
T98G brain cancer cells express high levels of the enzyme O6-methylguanine-
DNA methyltransferase (MGMT) that confers resistance to temozolomide (TMZ) 
(Christmann et al. 2011). Therefore, CTR compounds were used in combination 
with X-rays to determine the combinatorial effects, in which T98G cells were 
exposed to X-ray radiation simultaneously with CTR compounds (Chou 2006; 
Pearce et al. 2001). When cells were scheduled for radiation, the 96-well plates 
were treated with increasing doses of radiation (2-10 Gy) using a RS320 
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Radiation System (Gulmay Medical Inc. Scarborough, Canada). The plates were 
placed on the fourth shelf within the X-ray machine, on top of the Perspex plate 
to reduce backscatter. Cells received a dose ranging from 2-10 Gy (300 kV, 9 
mA) in 2-10 min respectively. The drug treatment was performed as outlined in 
section 2.2. The time point at which the cells were exposed to CTR-17 and CTR-
20 was considered as 0 h. After 72 h, the cells were fixed and the cytotoxicity 
was assessed using an SRB assay (section 2.2). Combination effects of CTR 
compounds and X-ray radiation were determined using two biological replicates.    
 
2.16 Statistical analyses 
All values were expressed as mean ± SEM of at least three independent 
experiments, unless stated otherwise. Analyses were performed using GraphPad 
Prism software. To determine any significant difference between two populations, 
an unpaired t-test was performed and a p-value of <0.05 was considered to be 
statistically significant.  
  
 
 
 
 
 
 
 
 
 
3.0 Results 
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3.1 CTR-17 and CTR-20 induce cell death in a cancer-specific manner and 
are equally potent against MDR cells 
Four CTR compounds (Figure 7) were initially short-listed from a series of 75 
chalcone-based derivatives by preliminary cytotoxicity screening performed at 
the Lee Lab. Subsequent screening of these CTR compounds using three breast 
cancer cell lines (MDA-MB231, MDA-MB468 and MCF-7) and two matching non-
cancer breast cell lines (184B5 and MCF10A) identified CTR-17 and CTR-20 as 
the most cancer-selective and efficient lead compounds (Table 1).  To determine 
the effect of CTR-17 and CTR-20 on the proliferation of different cancer cells, 
nine other cancer cell lines (HeLa, K562, Hek293T, RPMI-8226, U87MG, T98G, 
NCI-H1975, A-549 and UC-3) were exposed to increasing concentrations of 
CTR-17 and CTR-20 (Table 2). IC50 values were calculated from sigmoidal dose-
response curves (Figure 8) and the resultant data showed that CTR-17 and CTR-
20 kill most of the cancer cells 10-25 times more effectively than non-cancer cell 
lines, which is a highly desirable property of anti-cancer agents. When comparing 
the cytotoxic activity of colchicine in cancer and non-cancer cell lines, CTR-17 
and CTR-20 exhibit much better selectivity than colchicine, which is only about 
two to three fold more selective for cancer cells (Table 3). More attractively, CTR 
compounds inhibit the proliferation of multi-drug resistant cell lines with almost 
equal potency to the parental cells (Figure 9 & Table 4). The IC50 values indicate 
that both CTR-17 and CTR-20 kill the multidrug resistant (KB-C2, H69AR) and 
sensitive (KB-31, SW1271) cells with similar potency. Colchicine, paclitaxel, and 
vinblastine kill KB-C2 cell line more than 10 fold less than the parental KB-31 
cells.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Chemical Structures of the CTR compounds 
These quinolone chalcone hybrids were synthesized by our collaborators at the 
Rajiv Gandhi Technical University of India and subsequently sent to the Lee Lab 
for further analysis. Chemical names are provided below each compound 
structure.  
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Figure 8: Representative dose-response curves that were used to calculate 
the IC50 values 
A: A representative sigmoidal dose-response curve of HeLa cells treated with 
different concentrations of CTR-17 for 72 h.  
B: A representative sigmoidal dose-response curve of HeLa cells treated with 
different concentrations of CTR-20 for 72 h.  
The curves represent the values obtained by at least three independent 
biological replicates, with quadruple technical replicates for each set using 
GraphPad Prism v.5.04 software. 
 
59 
 
A 
 
 
 
 
 
 
 
 
 
B 
Log Concentration of CTR-17 (M)
P
e
rc
e
n
ta
g
e
 c
e
ll
 s
u
rv
iv
a
l
-2 -1 0 1 2 3
0
20
40
60
80
100
120
Log Concentration of CTR-20 (M)
P
e
rc
e
n
ta
g
e
 c
e
ll
 s
u
rv
iv
a
l
-2 -1 0 1 2 3
0
20
40
60
80
100
120
60 
 
 
 
 
 
 
 
Table 1: Initial screening of four CTR compounds using breast cancer cells 
(MDA-MB231, MDA-MB468, MCF7) and non-cancer breast cells (184B5, 
MCF10A) determined by SRB assays 
CODE 
IC50 (µM)a,b 
MDA-MB231 MDA-MB468 MCF7 K562 HeLa 184B5d MCF10Ad 
CTR-17c 0.41±0.02 0.15±0.33 0.52±0.17 0.15±0.10 0.33±0.06 3.49±0.03 3.95±0.14 
CTR-18 0.93 0.08 0.12 0.21±0.02 ND 3.89 NDe 
CTR-19 5.11 1.91 1.93 0.95±0.65 ND 3.94 ND 
CTR-20c 0.12±0.09 0.12±0.02 0.14±0.06 0.13±0.02 0.10±0.02 1.24±0.06 2.37±0.21 
Chloroquine 22.52 28.58 38.44 ND ND 76.13 ND 
Cisplatin 23.65 31.02 25.77 ND ND 25.54 ND 
a IC50 values were calculated from sigmoidal dose response curves (variable slope), which were 
generated with GraphPad Prism V. 4.02 (GraphPad Software Inc.).  
b Values are the mean value of triplicates of at least two independent experiments. 
c The IC50 values for CTR-17 and CTR-20 are represented as mean ± SEM (N=3). 
d The 184B5 and MCF10A are non-cancer, immortalized breast epithelial cell lines, and the rest 
are different cancer cell lines. 
e ND, not determined. 
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Table 2: Antiproliferation effects of CTR-17 and CTR-20 on other cancer 
cells 
 
IC50 (µM)a 
 U87MG 
(brain) 
T98G 
(brain) 
NCI-H1975 
(lung) 
A549 
(lung) 
RPMI-8226 
(myeloma) 
UC3 (Urinary 
Bladder) 
Hek293T 
(kidney) 
CTR-17 0.76 
±0.10b 
0.82 
±0.09 
0.60 
±0.14 
0.41 
±0.06 
0.36 
±0.04 
0.39 
±0.03 
0.42 
±0.07 
CTR-20 0.49 
±0.13 
0.22 
±0.10 
0.39 
±0.14 
0.13 
±0.04 
0.23 
±0.00 
0.12 
±0.03 
0.19 
±0.00 
a The IC50 values for CTR-17 and CTR-20 are represented as mean ± SEM (N=3) 
b Numbers are IC50 values in µM, determined by SRB assays as described in Table 1.  
 
 
 
 
 
 
 
 
 
 
 
Table 3: Comparison of the anti-proliferative activity of colchicine in cancer 
and non-cancer cells 
 
IC50 (nM)a 
 MDA-MB231 MDA-MB468 MCF7 HeLa 184B5 MCF10A 
Colchicine 5.70±0.49a 2.89±0.15 8.73±0.67 4.56±0.56 16.03±1.21 11.86±0.69 
a The IC50 values for colchicine are represented as mean ± SEM (N=3) 
b Numbers are IC50 values in nM, determined by SRB assays as described in Table 1.  
  
 
 
 
 
 
 
 
 
 
 
Figure 9: CTR compounds are cytotoxic towards cell lines overexpressing 
both MDR and MRP 
Western blotting of WCEs of drug-resistant cell lines and their parental wild type 
cells shows the overexpression of MDR1 and MRP1 for KB-C2 and H69AR cells, 
respectively. H69 cells grow as large multi-cell aggregates; hence, accurate cell 
counts were difficult. Therefore, cytotoxicity results obtained from H69AR cells 
was compared to SW1271 cells which are another small cell lung carcinoma cell 
line 
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KB-C2 KB-31 
MDR 1 
117kDa 
β-Actin 
43kDa 
H69AR H69 
MRP 1 
190kDa 
β-Actin 
43kDa 
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Table 4: Anti-proliferation effects of CTR compounds and other MTAs in 
multidrug resistant cell lines 
 
IC50a  
KB-31b
 
KB-C2 Resistance 
in fold SW-1271 H69AR
b Resistance 
in fold 
 
 Colchicine (nM) 5.36±0.54 83.45±7.22 15.57 4.84±0.80 22.97±3.63 4.74  
 Paclitaxel (nM) 2.01±0.17 23.08±0.21 11.48 4.51±0.71 10.99±2.60 2.44  
 Vinblastine (nM) 0.61±0.09 9.27±3.22 15.20 1.75±0.21 10.20±1.97 5.82  
 CTR-17 (µM) 0.38±0.07 0.65±0.16 1.71 1.14±0.04 0.52±0.10 0.45  
 CTR-20 (µM) 0.10±0.02 0.25±0.03 2.50 0.95±0.01 0.13±0.01 0.13  
a The IC50 values are represented as mean ± SEM (N=3) 
b The KB-C2 and H69AR are multidrug resistant cell lines that overexpress MDR1 and MRP1 
respectively. 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 10: Synergistic effects of CTR compounds and paclitaxel on cell 
proliferation inhibition in KB-C2 cells 
KB-C2 cells were plated in 96-well plates and treated with CTR-17, CTR-20, or 
paclitaxel alone, or with combinations of six different ratios of CTR-17 (or CTR-
20) to paclitaxel. The SRB assay was used to construct a sigmoidal dose-
response curve, from which the median effect dose (Dm), fraction affected (Fa) 
and slope of the curve (m) were determined. These values were then used to 
determine the combinational effect between CTR-17 or CTR-20 with paclitaxel, 
as outlined in methodology, section 2.2. Cell growth rates are represented as the 
mean ± SEM (N=4). 
A: The combination of CTR-17 and paclitaxel enhanced the cytotoxic abilities 
against the multidrug resistant KB-C2 cell line with CI values ranging from 0.71-
0.87.  
B: The combination of CTR-20 and paclitaxel enhanced the cytotoxic abilities 
against KB-C2 cell lines with CI values ranging from 0.69-0.95.  
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H69AR cells are usually more resistant to colchicine and vinblastine (about 5 
fold) than paclitaxel as paclitaxel is known to be a poor substrate for MRP (Glynn 
et al. 2004). Moreover, in combination with paclitaxel, both CTR-17 and CTR-20 
exhibited a synergistic mode of cell killing in Pgp overexpressing KB-C2 cells 
(Figure 10). The CI values for six different ratios of CTR compounds to paclitaxel 
were between 0.71-0.87 for CTR-17 with paclitaxel, and 0.69-0.95 for CTR-20 
with paclitaxel. According to previously published reports, all these combinations 
provide synergistic effects as the CI values are below 1 (Chou, 2006).  
 
In addition, Western blotting data of WCEs prepared from asynchronous HeLa 
cells showed that treatment with 3.0 µM CTR-17 caused cell death, as 
demonstrated by the increase in cleaved PARP in cancer cells but not in 184B5 
cells (Figure 11). 
 
3.2 CTR-17 induces a prolonged mitotic arrest that triggers cell death 
Flow cytometric analysis of propidium iodide stained cells showed that CTR-17 
treated cells undergo a prominent G2/M arrest within 12 h of the treatment, as 
demonstrated by the increase in the 4N DNA content (Figure 12). However, 
184B5 and MCF10A non-cancer cells returned to near-normal flow cytometry 
profile by 48 h post-treatment, although a substantial portion of 184B5 contained 
sub-G1 DNA content.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: CTR-17 caused cell death only in cancer cells 
Western blotting of WCEs prepared from asynchronous HeLa cells showed that 
treatment with 3.0 µM CTR-17 for 12-48 h causes cell death in cancer cells but 
not in 184B5 cells. 
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Figure 12: The majority of cancer cells arrested in G2/M by 12 h in the 
presence of 3.0 µM CTR-17 
A: 72 h post-treatment of HeLa cells with different concentrations (µM) of CTR-
17.  
B: Treated with 3.0 µM of CTR-17 and cell cycle progression was observed at 
different time points for 6-72 h. HeLa cells were collected, fixed and then stained 
with propidium iodide solution, and cell cycle positions were determined using 
flow cytometry.  
C: CTR-17 selectively increased cell cycle arrest and cell death in cancer cells. 
Breast cancer cells (MDA-MB468 and MDA-MB231), Human embryonic kidney 
293 cells that constitutively express the SV40 large T antigen (Hek293T) and 
non-cancer breast cells (184B5 and MCF10A) were treated with 3.0 µM CTR-17, 
stained with PI solution and analyzed by flow cytometry. MDA-MB468 cells 
undergo a prominent cell cycle arrest at G2/M phase and subsequently cell death 
as early as 48 h post-treatment. MDA-MB231 and Hek293T cells demonstrate 
prominent cell cycle arrests which accumulate with increases in exposure time to 
CTR-17. However, non-cancer breast cell line, MCF10A and 184B5 undergoes a 
less prominent cell cycle arrest, which seems to deteriorate with increase in 
exposure time, either with entrance to the cell cycle or minimal cell death. The 
data represents at least three independent experiments 
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CTR-17 did not cause an impediment to DNA replication as the percentage of 
Edu labeled cells was not significantly different (p > 0.05) between sham 
(29.11%) and CTR-17 (27.39%) treated cells (Figure 12). CTR-17 did not cause 
double-stranded DNA damage as γH2AX foci was not observed in sham or CTR-
17 treated cells in comparison to etoposide, even after 48 h of treatment (Figure 
13).  
 
Western blotting of WCEs prepared from asynchronous HeLa, Hek293T, MDA-
MB468 and MDA-MB231 cells provides further evidence that cells are arrested in 
mitosis when treated with CTR-17 (Figure 14). During the mitotic entry of 
eukaryotic cells, cdk1 activation is governed by multiple layers of regulation. 
Cdk1 remains in the inactive state during G2 by the phosphorylation on the Tyr15 
residue by wee1. As cells enter mitosis, cdk1 undergoes dephosphorylation on 
the Tyr15 residue by the cdc25C phosphatase and the level of wee1 reduces. On 
the other hand, cdk1 remain active by the phosphorylation on Thr161 caused by 
cdk activating complex (CAK).  In CTR-17 treated cells, cdk1 has undergone 
dephosphorylation on Tyr15 and phosphorylation on Thr161 within 12 h 
indicating that cdk1 is still active. In addition, the increase in cyclin B suggests 
that cyclin B-cdk1 complex is still intact, indicating that cells are in mitosis. The 
increase in phosphorylation of cdc25C on Thr48 (activating phosphorylation) and 
decrease in phosphorylation on Ser 216 (inhibitory phosphorylation) suggests 
that cdc25C is active. This positive feedback loop results in an extended 
activation of the cyclin B-cdk1 complex that prevents mitotic exit.  
  
 
 
 
 
 
 
 
Figure 13: CTR-17 has no significant effect on DNA replication and does 
not cause DNA damage 
A: Detection of EdU incorporated into DNA of HeLa cells treated with CTR-17 
showed that CTR-17 does not significantly affect DNA replication. Sham-treated 
or CTR-17 (3.0 µM) treated HeLa cells were incubated with culture medium 
containing 10.0 µM of EdU for one hour prior to 24 h. The cells were 
subsequently fixed and stained with a staining solution containing 1.0 µg/ml 
Alexa546-azide. After several washing steps, cells were then counterstained with 
Draq 5 and imaged by fluorescence microscopy. At least 10 different fields were 
analysed in three independent experiments to determine the percentage mean ± 
SEM of EdU labeled cells.   
B: Data from γH2AX staining shows that 3.0 µM CTR-17, even after incubation 
as long as 48 h, did not cause DNA double-stranded breaks. 50.0 µM of DNA-
damaging agent, etoposide, was used as a positive control to detect the γH2AX 
foci.  At least 10 different fields were analysed in three independent experiments.  
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a Percentage of EdU labeled cells are expressed as mean ± SEM (N=3) 
*p > 0.05 for sham-treated vs CTR-17 treated 
 Sham-treated 3.0 µM CTR-17 
% of EdU labeled cellsa 29±1* 27±4* 
Sham 
CTR-17 
3.0 µM, 24 h 
DRAQ 5 EdU Merge Bright field 
A 
Sham 
Etoposide 
50.0 µM, 48 h 
CTR-17 
3.0 µM, 48 h 
B 
DRAQ 5 Merge Bright field γH2AX 
  
 
 
 
 
 
 
 
Figure 14: CTR-17 arrested cells in mitosis not in G2 
Western blotting data of WCEs prepared from asynchronous (A) HeLa, (B) 
Hek293T, (C) MDA-MB468, and (D) MDA-MB231 showed that cells are arrested 
in mitosis when treated with 3.0 µM CTR-17 at different time points.  Equal 
protein samples were resolved by SDS-PAGE and immunoblotted using the 
antibodies against the proteins listed. GAPDH was used as a loading control. “p-“ 
denotes phosphorylation. Numbers above gels are post-treatment in hour (h) 
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To determine if CTR-17 affected the mitotic entry of the cells and to determine 
the exact stage of cell cycle arrest by CTR-17, HeLa cells were synchronised at 
the G1/S border and then released in the presence or absence of CTR-17 
(Figure 15). The similar patterns of cdk1 dephosphorylation on Tyr15 and 
phosphorylation on Thr161 in sham and CTR-17 treated cells suggest that cells 
enter mitosis without any impediment. Cyclin E has undergone complete 
degradation after 3 h in both sham and CTR-17 treated cells. However, unlike in 
sham-treated cells, cyclin E never reappears in CTR-17 treated cells at 12 h. 
This suggests that sham-treated cells have moved forward in the cell cycle, 
whereas CTR-17 treatment cause the cells to never move beyond mitosis. This 
conclusion is also strengthened by the continuous phosphorylation on serine 10 
residue of histone H3 in CTR-17 treated cells. The lack of cyclin B and securin 
degradation at least up to 20 h post-DT indicates that cells never enter anaphase 
in the presence of CTR-17, raising the possibility that cells are arrested at SAC 
activation step.  
 
Using immunofluorescence staining, changes in phenotype caused by CTR-17 
was analysed more closely using HeLa, Hek293T, MDA-MB468 and MDA-
MB231 cells. CTR-17 treatment caused an increase in the cell population with an 
abnormal mitotic morphology and prolonged mitotic arrest (Figures 16 and 17). 
The cells appeared to be rounded up with evidence of chromatin condensation. 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 15: CTR-17 prevents mitotic exit of HeLa cells released from 
synchronisation at the G1/S border 
A: Data shows flow cytometric profiles of HeLa cells synchronised at the G1/S 
border by double thymidine (DT) block and subsequent release into drug-free 
medium or medium containing CTR-17 (3.0 µM) for the indicated times.  
B: HeLa cells arrest at prometaphase-metaphase in the presence of CTR-17. 
Data shows Western blotting carried out with WCEs isolated from cells that had 
been arrested at G1/S by DT treatment and subsequently released into complete 
medium in the absence (sham) or presence of 3.0 μM CTR-17. Equal protein 
samples were resolved by SDS-PAGE and immunoblotted with antibodies 
against the proteins listed. GAPDH was used as the loading control. “p-“ denotes 
phosphorylation. Both flow cytometry profiles and Western blots show that mitotic 
progression is disturbed and mitotic exit is prevented. Data indicates: (1) By 6 h 
post-DT, most cells in the presence or absence of CTR-17 reach to G2/M; (2) by 
12 h post-DT, all of the cells in the sham control enter G1 of new cell cycle, while 
those treated with CTR-17 are trapped M phase; (3) by 48 h post-DT, most of the 
cells treated with CTR-17 are either still in M phase or undergo cell death.  
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Figure 16: CTR-17 treatment caused monopolar or uneven chromosome 
distribution 
Cells were treated (or not treated) with 3.0 µM CTR-17 for 12 h, fixed in methanol 
and stained with antibodies specific for gamma-tubulin (green) and alpha-tubulin 
(red), and then counterstained with DAPI (blue) to visualise the chromosomes.  
A: Sham-treated cells (top panels) are mostly in interphase and a higher 
magnification of a metaphase cell shows chromosomes positioned between the 
spindle poles equidistantly. However, CTR-17 treated cells (bottom panels) show 
groups of chromosomes (denoted by arrows) at the spindle poles which are 
incapable of resolving at the metaphase plate.  
B: Treatment of other cancer cells (Hek293T, MDA-MB468 and MDA-MB231) 
with 3.0 µM CTR-17 demonstrates a similar abnormal mitotic spindle that 
eventually leads to a monopolar or an abnormal chromosome division 
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Figure 17: CTR-17 selectively increased the mitotic index of cancer cells 
with an accumulation of abnormal and monopolar centrosomes 
A: CTR-17 selectively increased the percentage of cells in mitosis in a time-
dependent manner. Different cell types were either sham-treated or treated with 
3.0 µM CTR-17 for 12 h or 24 h. The mitotic index was determined by 
fluorescence microscopic analysis of about 200 cells for each cell type, either 
sham-treated or treated with CTR-17, and the data were expressed as 
percentage mean ± SEM of at least two independent experiments.  
B: Percentage of monopolar and abnormal chromosome division, under the 
same conditions as in (A) are tabulated. ACD denotes abnormal chromosome 
division among the mitotic cells. 
C: The average distance between the centrosomes of sham-treated vs cells 
treated with CTR-17 shows that the interpolar distance was about 35% less than 
in sham-treated cells. The average distance between the centrosomes were 
determined by fluorescence microscopic analysis of 100 cells in three 
independent replicates and the data were expressed as percentage mean ± SEM 
of at least three independent experiments. 
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 12 h post-treatment 24 h post-treatment 
Monopolar ACD Monopolar ACD 
HeLa 80.0±4.5 20.0±4.5 100.0±0.0 0.0±0.0 
MDA-MB231 40.0±10.2 60.0±10.2 44.9±5.7 55.1±5.7 
MDA-MB468 55.3±8.9 44.7±8.9 76.0±5.9 24.0±5.9 
HEK293T 50.5±10.1 48.2±10.1 93.2±3.4 0.1±0.0 
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The distance of two centrosomes in a single cell was shorter by 35% compared 
to sham-treated cells. CTR-17 treatment leads to: (1) abnormal chromosome 
division (ACD); and (2) monopolar centrosomes. The incidence of each 
phenotype varies among cells and depends on the stage of the cell cycle when 
CTR-17 is administered. If cells are in interphase during CTR-17 treatment, 
centrosomes may not be able to separate.  
 
This agrees with previously published reports which indicate the use of MTs in 
centrosome separation (Uzbekov et al. 2002). However, if the cells are already in 
mitosis, when CTR-17 is administered, the chromosomes may not be able to 
accurately resolve at the metaphase plate due to the absence of tension and 
attachment between the chromosomes and the mitotic spindle leading to ACD.  
 
The presence of unattached kinetochores results in the activation of SAC. To 
examine if CTR-17 causes mitotic arrest by SAC activation, BuBR1, one of the 
core proteins in the SAC complex was studied in detail. BubR1 associates with 
cdc20 (represented by red asterisks in Figure 18A) to inhibit the cdc20-mediated 
activation of the APC/C complex. To determine if BubR1 interacts with cdc20, 
BubR1 was immunoprecipitated and immunoblotted with an antibody specifically 
directed towards cdc20 at scheduled time points (6-9 h, post-DT). Nocodazole 
causes the activation of SAC, and hence was used as a positive control (Collin et 
al. 2013). Both nocodazole and CTR-17 arrest the cells at the SAC step where 
BubR1 is associated with cdc20, in comparison to the sham-treated cells. 
  
 
 
 
 
 
 
 
 
 
 
Figure 18: CTR-17 prevented mitotic exit by prolonged spindle checkpoint 
activation 
A: Immunoprecipitation of BuBR1 revealed its association with cdc20, rendering 
APC/C-cdc20 complex inactive and causing the spindle assembly checkpoint 
activation. HeLa cells synchronised at the G1/S boundary by double thymidine 
block and release were either sham-treated or treated with 20 ng/ml nocodazole 
or 3.0 µM CTR-17, and then harvested at the indicated time points. BuBR1 was 
immunoprecipitated from the whole cell lysates, and the immunoprecipitates were 
then resolved by SDS-PAGE and immunoblotted using an antibody specifically 
directed towards cdc20 (represented by red asterisks). WCEs were 
immunoblotted with cdc20 and used as the loading control.  
B: The presence of a slow migrating band of BubR1 in DT-synchronised CTR-17 
treated HeLa cells is another evidence of SAC activation.  
C: Representative images showing BuBR1 accumulation at the kinetochores of 
CTR-17 treated HeLa cells. HeLa cells were either sham or CTR-17 (3.0 µM) 
treated for 12 h. Cells were subsequently fixed and stained with anti-BubR1 and 
CENP-B, to stain the centromeres. Accumulation of BubR1 at the kinetochores 
indicates the lack of proper tension between the kinetochores and the mitotic 
spindle and thus the continuous activation of spindle assembly checkpoint. 
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When whole cell extracts (WCEs) isolated after DT-based synchronization were 
released in the absence (sham) or presence of 3.0 μM CTR-17 and then 
resolved by SDS-PAGE, a bandshift in BubR1 was observed in the CTR-17 
treated cells by 12 h post-DT (Figure 18B). This observation strongly agrees with 
previous reports that a phosphorylation-dependent band-shift occurs when cells 
are treated with MTAs (Taylor et al. 2001).  
 
BubR1 is reported to accumulate at the unattached kinetochores and to aid in the 
recruitment of other SAC proteins including CENP-E, Mad1, Mad2, Bub1 and, 
Bub3. Therefore, the localisation of BubR1 at unattached kinetochores was 
examined by using an antibody specifically directed towards CENP-B. CTR-17 
leads to the accumulation of BuBR1 at the kinetochores, suggesting that the 
APC/C-Cdc20 complex is inactive in CTR-17-treated cells, thus confirming SAC 
activation and inhibition of mitotic exit (Figure 18C).    
 
To determine if mitotic arrest caused by CTR-17 and CTR-20 was reversible, 
HeLa cells were treated for 12 h with CTR compounds and then the drug-
containing medium was removed, washed with 1X PBS, and replaced with fresh 
culture medium. The cells were harvested at scheduled time points and 
subjected to flow cytometry. The flow cytometry profiles showed that both CTR-
17 and CTR-20 are reversible and the cells progressed to the next cycle within 3-
6 h after washing (Figure 19).   
  
 
 
 
 
Figure 19: CTR-17 and CTR-20 causes a reversible mitotic arrest in HeLa 
cells 
A: HeLa cell cycle histograms show a G2/M cell cycle arrest in CTR-17 (3.0 µM) 
and CTR-20 (1.0 µM) treated cells after 12h (t=0 h). At t=0 h, the adherent and 
floating cells were washed separately twice with 1X PBS, followed by re-
suspension of the cells in 10 ml of pre-warmed, drug-free medium for the 
indicated duration.  
B: HeLa flow cytometry profiles show that CTR-17 and CTR-20 cause a 
reversible mitotic arrest, during which cells progress in the cell cycle and 
overcome the robust mitotic arrest as early as 3 h from the release.  
C: Treated HeLa cells released into drug-free medium progress normally in 
mitosis. Representative images of cells released into drug-free medium collected 
at the indicated time points. 
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3.3 CTR compounds inhibit MT polymerization 
The morphological features observed by the treatment of cells with CTR 
compounds were very similar to other MTAs such as vinblastine, nocodazole and 
podophyllotoxin (Jordan et al. 1992). CTR compounds caused aberrant mitotic 
spindles with a shorter distance between the spindle poles and some 
chromosomes remain at the spindle poles, leading to prolonged mitotic arrest 
with disregulated chromosome alignment. Hence, the effect of CTR compounds 
on the MT polymerization was examined using an in vitro MT assembly assay 
(Figure 20). A polymerization curve was then constructed to represent 3 stages 
of the MT polymerization process, including MT nucleation, growth, and finally 
the steady state equilibrium. If a compound interacts with MT, one of the above 
phases should be altered. For example, paclitaxel, an MT stabilizer, completely 
eliminates the nucleation phase and achieve steady state equilibrium in a shorter 
duration (Schiff et al. 1979). In contrast, nocodazole, an MT destabilizer shows a 
longer growth phase and achieves a steady state after an extended period of 
time in the process of MT assembly (Chao et al. 2002). Data in Figure 20 shows 
that CTR-17 and CTR-20 cause an inhibition of MT polymerization; whereas, 
paclitaxel promoted MT assembly. Similarly to CTR compounds, nocodazole 
inhibited MT polymerization. It is noted that CTR-17 and CTR-20 showed a 
prolonged MT growth phase and took a longer time to reach a steady equilibrium 
state (≥60 min). In contrast, paclitaxel reached equilibrium as early as 18 min. 
According to the experimental set up, (i.e., a working volume of 100 µl and a path 
length of 0.5 cm), OD 0.1 at 340 nm is approximately equivalent to 1.0 mg/ml of 
MT polymer mass.  
  
 
 
 
 
 
 
 
 
Figure 20: CTR-17 and CTR-20 inhibit the polymerization of purified tubulin 
10.0 µM paclitaxel, 3.0 µM CTR-17, 1.0 µM CTR-20 or 5.0 µM nocodazole were 
added to reaction mixtures containing purified porcine tubulin in G-PEM buffer. 
Polymerization of tubulin was then monitored at 340 nm and 37°C using a 
spectrophotometer every 1 min for one hour. CTR-17 and CTR-20 cause an 
extended growth phase and takes a longer duration to achieve steady state 
equilibrium, similar to nocodazole but contrarily to paclitaxel, indicating that they 
are inhibitors of tubulin polymerization. The Figure is a representative of at least 
three independent experiments.  
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Hence, paclitaxel, G-PEM buffer control, CTR-17, CTR-20 and nocodazole 
polymerised about 55%, 40%, 30%, 25% and 24%, respectively, at 30 min. 
Therefore, CTR-17 and CTR-20 were identified as MT polymerization inhibitors.  
 
Live cell imaging using sham or CTR-17 (3.0 µM) treated Hek293T cells 
transfected with GFP-tubulin showed that CTR-17 led to the formation of 
aberrant spindles (Figure 21). The centrosomes were unable to establish the 
bipolarity of the cells for as long as 24 h. As a result, normal cell cycle 
progression was disrupted and mitotic exit is prevented, strongly agreeing with 
the data obtained from immunofluorescence, immunoblotting and flow cytometry 
experiments. 
 
The effect of CTR compounds on MT polymerization in the cell was then 
determined. Intracellular tubulin occurs in two forms, namely the polymerized 
(cytoskeletal) tubulin and monomeric (soluble) tubulin. MT stabilizers and 
destabilizers lead to the accumulation of polymerized and soluble tubulin, 
respectively (Stanton et al. 2011). To confirm the inhibition of MT polymerization 
of CTR compounds, the polymerised and soluble tubulin fractions were 
separately extracted and examined by immunoblotting. Similarly to nocodazole 
(50 ng/ml), both CTR-17 (3.0 µM) and CTR-20 (1.0 µM) reduced the polymerized 
pool of tubulin by 12 h of treatment in HeLa cells (Figure 22). This phenomenon 
was also observed in a dose-dependent manner in HeLa cells.  
  
 
 
 
 
 
 
 
Figure 21: CTR-17 leads to disrupted spindle bipolarity 
A: Sham-treated Hek293T cells transfected for 16 h using CellLight® Tubulin-
GFP shows the bipolar spindle formation (indicated by a white arrow) followed by 
the completion of cell division and the separation of the cell into two daughter 
cells. 
B: CellLight® Tubulin-GFP transfected Hek293T cells treated with CTR-17 tries 
to develop the spindle. However, they are apparently unable to maintain an 
adequate distance between the centrosomes (indicated by a yellow arrow) and, 
eventually, collapse to a monopolar spindle configuration towards the end of the 
capture (indicated by a red arrow). 
. 
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Figure 22: CTR-17 and CTR-20 decreased the polymerized pool of tubulin 
A: HeLa cells were either sham-treated or treated with 50.0 nM paclitaxel, 50.0 
ng/ml nocodazole, 3.0 µM CTR-17 and 1.0 µM CTR-20 for 12 h. Lysates were 
subsequently separated into polymerized (Pol) and soluble (Sol) fractions, and 
then equal amounts of proteins were resolved by SDS-PAGE and immunoblotted 
with an antibody specific to alpha-tubulin. The graphs below each blot represent 
densitometry of the tubulin band intensities in each fraction. The results 
represent the mean ± SEM of at least three independent experiments.  CTR 
compounds reduced the polymerized fraction of tubulin similar to nocodazole, but 
contrarily to paclitaxel. Pac and Noc denote paclitaxel and nocodazole, 
respectively. 
B: CTR-17 and CTR-20 reduced the polymerized tubulin fraction dose-
dependently in HeLa cells.  
C: The MT destabilizing effect of CTR compounds were common in other cell 
lines, MDA-MB231 and MDA-MB468.  
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When examined in other cell lines, including MDA-MB231 and MDA-MB468, the 
same effect was observed. However, paclitaxel (50 nM) caused the polymerised 
fraction of tubulin to increase in all cell lines as expected for a well-known MT 
stabilizing agent. Hence, CTR compounds are MT polymerization inhibitors in 
multiple cell lines.  
 
3.4 CTR compounds reduced the migration abilities of MDA-MB231 cells 
In addition to the disruption of cell cycle progression, MTAs also interfere with the 
migration capability of cells (Goldman 1971; Small et al. 2002). Many studies 
have shown that MTAs inhibit mitosis by abrogating the dynamic behaviour of the 
plus-ends of the MT (Jordan & Wilson 2004). This alteration in MT dynamicity 
was used to explain the inhibition of cell migration by agents that interfere with 
MTs (Pourroy et al. 2006).  
 
Hence, the effect of CTR-17 on the migration ability of MDA-MB231 cells in 
comparison to a sham-treated cell population for a period of 72 h was examined 
(Figure 23A). For the scratch wound healing assay, a scratch was introduced 
using a p200 pipette tip on a monolayer of MDA-MB231 cells and then the cells 
were either sham-treated or treated with 3.0 µM CTR-17 before being subjected 
to live cell microscopy. The cell images were captured every 10 min for 72 h and 
the percentage of wound closure was measured using Image J software, an 
open access software developed by the National Institute of Health 
(rsb.info.nih.gov/ij). 
  
 
 
 
 
 
 
Figure 23: CTR-17 disrupted the wound healing ability of MDA-MB231 cells 
A: Live cell images of confluent MDA-MB231 cells containing a scratch wound 
that were either sham-treated or treated with CTR-17 for up to 72 h. Images were 
taken using a 4X objective and every 10 min intervals.  
B: The values show the mean ± SEM of the percentage of wound closure (N=3).  
C: Figures are presented as a bar graph. The percentage of wound closure was 
calculated using Image J software in triplicates for each field, and each 
experiment was performed in triplicates.  
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0 0 0 
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36 66.22±5.95 18.49±2.38 
48 78.10±2.54 32.91±2.12 
60 84.27±4.77 45.47±11.11 
72 92.60±7.43 50.64±9.94 
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Sham-treated cells led to approximately 93% wound closure within 72 h; 
however, CTR-17 treated cells were only able to close the wound by 51% (Figure 
23B). Looking closely at the velocity of wound closure, sham-treated cells closed 
the wound at a rate of ~10.0 µm/h, while CTR-17 treated cells closed the wound 
at approximately half of the velocity. Previous studies showed that MTAs cause 
the microtubules to be more static and are hence unable to remodel the 
cytoskeleton for the purpose of changing the shape of the cell during the cell 
migration (Yang et al. 2010). These observations further support the ability of 
CTR compounds to manifest themselves as MT interfering agents. 
 
3.5 CTR compounds bind directly to purified tubulin 
To determine if CTR compounds directly bind to tubulin and cause any changes 
in its tertiary structure, the fluorescence of tryptophan residues was monitored. 
Intrinsic tryptophan fluorescence of tubulin is now widely used as a probe to 
determine the binding affinity of drugs to tubulin heterodimers (Zhang et al. 2009; 
Venghateri et al. 2013; Rai et al. 2012; Gireesh et al. 2012). The fluorescence of 
the reaction mixture in the absence of any drug (but in the presence of DMSO or 
PIPES buffer) with tubulin was relatively higher than all the drug concentrations 
used. Data in Figure 24 shows a concentration-dependent quenching of the 
tryptophan fluorescence when purified tubulin was incubated with CTR-17 or 
CTR-20. For example, the incubation of 10.0 µM and 40.0 µM of CTR-17 with 
tubulin quenched the intrinsic fluorescence of tubulin by 34.3±1.6% and 
46.4±3.6%, respectively (Figure 24A).  
  
 
 
 
 
 
 
 
Figure 24: CTR-17 and CTR-20 bound to purified tubulin 
A, B: CTR-17 and CTR-20 quenched the intrinsic tryptophan fluorescence of 
tubulin in a dose-dependent manner. Tubulin (0.4 µM) dissolved in 25 mM PIPES 
buffer (pH 6.8) was incubated in the absence or presence of different 
concentrations of CTR compounds for 30 min at 37°C.  Fluorescence was then 
monitored by excitation of the reaction mixture at 295 nm and the emission 
spectra were recorded at 315-370 nm.  
C, D: The changes in fluorescence were plotted against the concentration of the 
drugs to determine the dissociation constant. The dissociation constants suggest 
that CTR-17 and CTR-20 bind with comparable ability to tubulin. ∆F is the 
change of fluorescence intensity of tubulin when bound to CTR-17 or CTR-20. 
Data are the average of at least five independent experiments. 
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The incubation of 10.0 µM and 40.0 µM of CTR-20 similarly reduced the intrinsic 
fluorescence of tubulin by 21.5±1.0% and 32.5±1.7%, respectively (Figure 24B). 
The changes in fluorescence intensity were determined relative to PIPES buffer, 
and the binding constants (Kd) were then determined by fitting the fluorescence 
changes in a binding isotherm for CTR-17 (Figure 24C) and CTR-20 (Figure 
24D). During each experiment, no-tubulin controls (each concentration of drug 
only in PIPES buffer) were used to deduct any inherent fluorescence of the CTR 
compounds alone. The Kd values were found to be 4.58±0.95 µM and 5.09±0.49 
µM from five independent experiments for CTR-17 and 20, respectively.  
 
3.6 CTR compounds bind to tubulin partially overlapped to the colchicine-
binding site 
To pinpoint the exact binding site of the CTR compounds, competition assays in 
the presence of BODIPY® FL Vinblastine and colchicine were performed, as 
most of the MT polymerization inhibitors bind to tubulin via the colchicine or 
vinblastine-binding sites (Zhang et al. 2009). Upon binding to tubulin, the 
fluorescence intensity of colchicine and BODIPY® FL Vinblastine increases, 
which was used as an index to determine if CTR-17 and CTR-20 compete with 
either colchicine or vinblastine in binding to the respective target sites. The CTR 
compounds and colchicine were unable to inhibit the fluorescence enhancement 
caused by BODIPY® FL Vinblastine binding to tubulin, even at a high 
concentration of 25 µM; however, vinblastine did reduce the fluorescence of the 
BODIPY® FL Vinblastine-tubulin complex. This suggests that CTR compounds 
do not bind to the vinblastine site (Figure 25A).  
  
 
 
 
 
 
 
Figure 25; CTR-17 and CTR-20 do not bind to the vinblastine-binding site 
A: CTR-17 and CTR-20 do not quench the fluorescent enhancement of BODIPY 
FL vinblastine-tubulin complex, similarly to colchicine but contrary to vinblastine. 
Tubulin (0.4 µM) was incubated with 25.0 µM of CTR-17, CTR-20, colchicine, 
vinblastine for one hour at 37°C and 5.0 µM of BODIPY® FL Vinblastine was 
then added to the tubulin complexes and incubated under the same conditions 
for additional 30 min. Fluorescence was then monitored by excitation of the 
reaction mixture at 490 nm and the emission spectra were recorded at 510-550 
nm.  
B: Unlike vinblastine, CTR-17 inhibits the fluorescence enhancement of the 
colchicine-tubulin complex in a dose-dependent manner. Tubulin (0.4 µM) was 
incubated with different concentrations of CTR-17 or vinblastine for one hour at 
37°C, and then 5.0 µM of colchicine was added to the tubulin complexes, 
followed by incubation for 30 min under the same conditions. Fluorescence was 
then monitored by excitation of the reaction mixture at 360 nm and emission was 
recorded at 430 nm. F is the fluorescence of the CTR-17-colchicine-tubulin or 
vinblastine-colchicine-tubulin complexes, and F0 is the fluorescence of the 
colchicine-tubulin complex. Each experiment was repeated at least twice more.  
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However, the fluorescence of the colchicine-tubulin complex was reduced in a 
concentration-dependent manner by the CTR compounds, suggesting that both 
CTR-17 and CTR-20 bind to tubulin at or near the colchicine-binding site. Figure 
25B shows the change in fluorescence of the colchicine (5 µM)-tubulin complex, 
when incubated with vinblastine or CTR-17 at the same concentration. Unlike 
vinblastine, CTR-17 reduced the fluorescence of the complex in a dose-
dependent manner. To determine the mode of inhibition of the CTR compounds, 
different concentrations of colchicine were used. For example, 1, 3, 10 and 20 
µM CTR-17 decreased the fluorescence of the colchicine (3 µM)-tubulin complex 
by 44±6%, 59±6%, 65±4% and 74±7%, respectively, and colchicine (5 µM)-
tubulin complex by 30±4%, 44±6%, 53±3% and 67±6% (Figure 26A). CTR-20, 
when bound to tubulin, caused an enhancement of fluorescence at the same 
wavelength; therefore, the concentration range of CTR-20 was reduced. This 
may be because CTR-20 binds to the colchicine site more strongly than CTR-17. 
For example, 0.5, 1.5 and 3.0 µM CTR-20 decreased the fluorescence of the 
colchicine (3 µM)-tubulin complex by 27±11%, 34±8% and 59±11%, respectively, 
and colchicine (5 µM)-tubulin complex by 18±7%, 29±10% and 37±8% (Figure 
26B). Thereafter, modified Dixon plots (Figures 25C and D) were constructed to 
determine the inhibition constants (Ki) and the mode of inhibition of the CTR 
compounds. An intersecting family of lines were obtained in a Dixon plot by 
plotting 1/F versus the inhibitor concentration (CTR) for each substrate 
concentration (colchicine).  
  
 
 
 
 
 
 
 
Figure 26: CTR-17 and CTR-20 bind partially overlapping to the colchicine-
binding site 
A: CTR-17 and CTR-20 reduces the fluorescence enhancement of different 
concentrations of colchicine-tubulin complexes. CTR-17/CTR-20-tubulin 
complexes containing increasing concentrations of CTR-17 or CTR-20 were 
incubated for 30 min with different concentrations of colchicine, and the 
fluorescence of the final tubulin complex was determined by exciting the 
complexes at 360 nm and recording their emissions at 430 nm.  
B: Modified Dixon plots for both the CTR compounds show a competitive mode 
of inhibition and the Ki values were 5.68±0.35 µM and 1.05±0.39 µM for CTR-17 
and CTR-20, respectively. F is the fluorescence of the CTR-17- or CTR-20-
colchicine-tubulin complexes, and F0 is the fluorescence of the colchicine-tubulin 
complex. Data are the average of at least four independent experiments. 
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These lines converge and intersect above the x-axis, which in this case of a 
competitive inhibitor, and on the x-axis in the case of a non-competitive inhibitor. 
The value of the inhibitor concentration, where the lines intersect, shows the Ki 
value. Ki values signify the concentrations of the inhibitor (in this case, CTR 
compounds) required to cause half of the maximum inhibition (Cornish-Bowden 
1974). The mode of inhibition was found to be competitive for both the CTR 
compounds, and the Ki values were determined to be 5.68±0.35 µM and 
1.05±0.39 µM from four independent experiments for CTR-17 and CTR-20, 
respectively. These values suggest that the concentration of CTR-20 required to 
inhibit 50% of binding ability of colchicine to tubulin is about five times less than 
CTR-17, indicating that CTR-20 binds at or near the colchicine site about five 
times more efficiently than CTR-17.   
 
Computation-based docking study was carried out to provide further evidence in 
determining the binding site of the CTR compounds. Data from the molecular 
modeling is consistent with the conclusion that CTR-17 and CTR-20 interact with 
tubulin at close proximity to the colchicine-binding site. These two chalcone 
derivatives embed well within the colchicine binding pocket and are stabilized by 
both covalent and non-covalent interactions (Figure 27). There are 10 amino 
acids commonly found surrounding both colchicine and CTR-20 (Figure 27, red 
squares), 19 amino acids surrounding both colchicine and CTR-17 (Figure 27, 
yellow squares) and 10 amino acids surrounding both CTR-17 and CTR-20 
(Figure 27, blue squares).  
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: Docking poses of CTR-17 and CTR-20 at the colchicine-binding 
site 
Interactions between tubulin heterodimer (PDB code: 1SA0) and colchicine (A), 
CTR-20 (B), and CTR-17 (C) are shown in 3D pattern in the left panels. 2D 
ligand interaction diagrams show the bonds and amino acids within a distance of 
4 Å to colchicine (A’), CTR-20 (B’) and CTR-17 (C’). There are three hydrogen 
(H) bonds between the tubulin and colchicine, and two and one H bonds between 
tubulin and CTR-20 and CTR-17, respectively. Green arrow denotes that the H 
bond is formed via the side chain, and the blue arrow via the backbone of the 
amino acid. A number of hydrophobic and polar residues show overlap in 
colchicine and two CTR compounds’ docking images. Amino acids which are 
common to colchicine and CTR-20 are within red boxes, amino acids common to 
colchicine and CTR-17 are in yellow boxes, and amino acids that are common to 
CTR-17 and CTR-20 are in blue boxes. Polar residues are shown in pink and 
hydrophobic resides in green. Basic residues contain a blue ring and acidic 
residues a red ring. Atoms in the ligand surrounded by a blue cloud indicates the 
surface area of the ligand atoms exposed to the solvent, and light blue clouds 
around the amino acid residues denote the strength of the interaction. The dotted 
lining indicates the steric possibility of a methyl group substitution and the dotted 
lining is broken if the ligand is close to a fully exposed atom.  
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There are three hydrogen bonds between the tubulin and colchicine. The 
direction of the arrows suggests that colchicine is the donor of one hydrogen (H) 
bond and the tubulin moiety is the donor of the other two hydrogen bonds. The 
green arrows indicate that the H bonds are formed with the side chains of the 
amino acid residues and the blue arrow shows that it is formed with its backbone 
(Deschênes & Sourial 2007). CTR-20 forms two H bonds and an arene-cation 
interaction with the tubulin moiety. CTR-20 is the donor of one H bond and 
tubulin donates the other H bond and both are formed with the side chains of the 
amino acid residues. CTR-17 is the donor of the single H bond that is formed 
with the back bone of the amino acid. Surrounding amino acids in the ligand 
interactions are within 4 Å distance and stabilizes the interaction between each 
compound and the tubulin moiety by Van der Waals forces.   
 
In spite of striking differences in the structures of colchicine, podophyllotoxin and 
the two CTR compounds, all of these compounds can occupy the same binding 
pocket within the tubulin moiety as demonstrated by the overlapping docking 
images (Figure 28).  
 
3.7 Specificity of CTR compounds in preferential cancer cell killing is 
neither due to a shorter doubling time of cancer cells nor differences in cell 
permeability  
To determine if the cancer-cell specificity of the CTR compounds is due to the 
shorter doubling times of cancer than non-cancer cells, the doubling times of four 
cancer cell lines and two non-cancer cell lines were determined.  
  
 
 
 
 
 
Figure 28: CTR-17 and CTR-20 overlap colchicine and podophyllotoxin-
binding sites 
A: The overlap of tubulin-bound colchicine (blue), CTR-17 (green), CTR-20 
(magenta), podophyllotoxin (yellow) and vinblastine (red) in the 3D X-ray 
structure of tubulin (PDB code: 1SA0).  
B: The structures of colchicine (blue), CTR-17 (green), CTR-20 (magenta) and 
podophyllotoxin (light red) are shown to aid the visualization of the overlap when 
bound to tubulin. 
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The differences in doubling times, determined from the growth curves of each 
cell line (Figure 29) are not found to be justifying the preferential cancer cell 
killing of the CTR compounds (Table 5). The two non-cancer cell lines that were 
used for the study were (1) 184B5, a chemically transformed, immortalized, non-
malignant breast cell line, and (2) MCF10A, which is a non-tumorigenic breast 
epithelial cell line. As summarized in Table 6, the doubling times of HeLa, MDA-
MB231, MDA-MB468, Hek293T, MCF10A, and 184B5 were 24 h, 25 h, 39 h, 16 
h, 20 h and 26 h respectively. These doubling times are similar to those 
previously determined by others. For example, the doubling times for HeLa, 
MDA-MB231, MDA-MB468, Hek293T, MCF10A and 184B5, according to 
previous publications were about 24 h (Rahbari et al. 2009), 28 h (Limame et al. 
2012), 48.5 h (Iyer et al. 2013), 16-20 h (Kamei et al. 2011), 26 h (Molitor & 
Traktman 2013) and 18 h (Zajchowski et al. 1993), respectively.  
 
To determine if the doubling times reflect the cytotoxicity caused by the CTR 
compounds in different cell lines, linear regression analysis was performed 
(Dariolli et al. 2013). The results showed that there was no relationship between 
the doubling times of the cell lines and the cytotoxicity caused by CTR-17 and 
CTR-20. When the degree of cytotoxicity of CTR-17 or CTR-20, expressed as 
the Mean IC50 values were plotted against the doubling times of different cell 
lines, the slopes of the regression line, R2 values, and the p values were -0.044, 
0.041, and 0.701 for CTR-17 and -0.009, 0.007, and 0.878 for CTR-20 
respectively (Figure 30).  
  
  
 
 
 
 
 
 
 
 
 
 
 
Figure 29: The difference in doubling times in cancer and non-cancer cells 
do not justify the cancer cell specificity of the CTR compounds 
Proliferation curves of HeLa, MDA-MB231, MDA MB-468, Hek293T, 184B5 and 
MCF10A show the essential features of a typical growth curve that includes a lag 
phase, an exponential log phase and a stationary phase.  
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Table 5: IC50 values of CTR-17 and CTR-20 
 
 
  
 
 
 
Table 6: Doubling times of cancer and non-cancer cells 
 
 Doubling time (h) 
HeLa MDA-MB231 MDA-MB468 Hek293T 184B5 MCF10A 
Trial 1 (Trypan blue) 19.52 25.18 NDa ND 17.62 21.3 
Trial 2 (SRB) 21.12 21.67 37.32 18.51 21.24 22.59 
Trial 3 (SRB) 31.81 26.61 40.8 12.69 21.09 35.15 
Mean ± SEM 24.2±3.9 24.5±1.5 39.1±1.7 15.6±2.9 19.9±1.2 26.4±4.4 
a ND, not determined. 
 
 HeLa MDA-MB231 MDA-MB468 Hek293T 184B5 MCF10A 
       
CTR-17 0.33±0.06a 0.41±0.02 0.15±0.33 0.42±0.07 3.49±0.03 3.95±0.14 
CTR-20c 0.10±0.02 0.12±0.09 0.12±0.02       0.19±0.00 1.24±0.06 2.37±0.21  
a Numbers are IC50 values in µM, determined by SRB assays as described in Table 1. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30: Cytotoxicity caused by CTR compounds is not related to the 
doubling times of different cells 
A: Linear regression analysis of the mean IC50 values of CTR-17 and the 
doubling times of different cell lines. 
B: Linear regression analysis of the mean IC50 values of CTR-20 and the 
doubling times of different cell lines. 
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The negative slopes suggest that the mean IC50 values increase, while the 
doubling time decreases and vice versa. However, if at all the doubling times and 
cytotoxicity were related, we would expect the faster growing cells (lower 
doubling times), such as 184B5 and Hek293T to be more responsive to the drugs 
(lower IC50 values) than the slower replicating cells, like MDA-MB468. This is 
because CTR compounds are MT inhibitors and highly proliferating cells would 
be more susceptible to these agents as MT organization is crucial for mitosis 
(Stanton et al. 2011). However, the IC50 values show that this was not the case, 
as 184B5 cell line was one of the more resistant cell lines to both CTR-17 (3.49 
µM) and CTR-20 (1.24 µM) as compared to slower growing MDA-MB468 (CTR-
17:0.15 µM and CTR-20:0.12 µM). 
 
The R2 value determines if the values in X and Y axes follow a linear relationship. 
When the R2 value is closer to 1, this suggests that the values fall on straight line 
with no random scatter, however when R2 value is closer to 0, this suggests that 
that values in X and Y axes are not related. The R2 values for both CTR-17 
(0.044) and CTR-20 (0.007) suggest that the mean IC50 values and the doubling 
times are not related. The p value determines the probability of values to lie on a 
regression line away from the horizontal, the null hypothesis being that the 
overall slope equals zero (no linear relation between X and Y axes). The p 
values, in both CTR-17 (0.701) and CTR-20 (0.878) indicates that the slopes are 
not significantly deviating from a zero slope, indicating a poor goodness-of-fit and 
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no relation between the doubling times and the levels of cytotoxicity by both the 
CTR compounds (Dariolli et al. 2013).  
 
Since the doubling times were not distinctly different between cancer and non-
cancer cells, the differences in permeability of cancer (MDA-MB231) and non-
cancer (184B5) cell line to CTR-17 were evaluated. Both the cell lines were 
exposed to 3.0 µM CTR-17 and harvested at the scheduled time points. The 
intracellular concentration of CTR-17 was then determined in the cell lines using 
HPLC and expressed as the area of CTR-17 peak per µg of protein in each cell 
line (Figure 31). In sham-treated cells and at 0 h, there was no CTR-17 found in 
both types of cells. When cells were incubated for longer periods of time, the 
amount of CTR-17 (area of the peak per µg of protein) was 14.57, 18.02, and 
20.41 at 6 h, 12 h, and 24 h respectively, in 184B5 cells and 13.13, 13.98, and 
17.93 at 6 h, 12 h, and 24 h in MDA MB-231 cells. Hence, there was no 
significant difference in the concentration of CTR-17 within both the cell types. 
This may be because CTR-17 is a small molecule with molecular weight of 
305.33 kDa, hence, apparently there is no differential permeability between 
cancer and non-cancer cells. Interestingly, 184B5 cells were actually slightly 
more permeable to CTR-17 than MDA-MB231 cells. However, the degree of 
cytotoxicity and mitotic arrest, caused by CTR compounds is clearly distinct 
among the cancer and non-cancer cells. Therefore, the mechanism of 
preferential cancer cell killing by CTR-17 and CTR-20 is still to be elucidated. 
  
 
 
 
 
 
 
 
 
 
Figure 31: The intracellular concentration of CTR-17 does not correlate with 
the specificity of CTR compounds 
A: HPLC profile of CTR-17 (0.5 mg/ml) standard at retention time of 5.88 min.  
HPLC conditions included an injection volume of 5.0 µl of the CTR-17 into an 
ultra C18 column (4.6 mm X 150 mm, 3.0 µm). Detection at 350 nm for 10 min. 
Mobile phase consisted of an isocratic system of methanol to water at a ratio of 
70:30 (v/v) with a flow rate of 0.75 ml/min. 
B: The intracellular concentration of CTR-17, represented here as the area of the 
peak/µg of protein, is not significantly different between MDA-MB231 and 184B5 
cells. Both cell lines were treated with 3.0 µM CTR-17 for the scheduled time 
points. Cells were washed twice, harvested and lysed with lysis buffer and 
sonication. The proteins were then precipitated out from the extracts and filtered 
before performing HPLC.   
C: The bar graphs show that the intracellular concentration of CTR-17 is not 
significantly different between MDA-MB231 and 184B5 cells (p>0.05, using an 
unpaired t-test). Data presented in the bar graphs are mean ± SEM of two 
independent experiments.    
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3.8 CTR compounds do not radiosensitize T98G cells 
Temozolomide (TMZ)-based chemotherapy along with neurosurgery has proven 
to be successful in the treatment of glioblastoma multiforme (GBM) (Huang et al. 
2012). However, resistance to this treatment occurs in some patients. TMZ is an 
alkylating agent that methylates several residues including N7 of guanine, N3 
and O6 of adenine. The O6 methylation is repaired by the enzyme, MGMT. 
Increased expression of MGMT levels is associated with resistance to TMZ 
(Montaldi & Sakamoto-Hojo 2013; Bobola et al. 1995). The combinatorial effects 
of CTR compounds and X-ray radiation were assessed using three different 
concentrations of CTR-17 and CTR-20. To establish a lesser toxic combinatorial 
regimen, the IC50 concentrations and two more concentrations below it were 
used, for each compound against the T98G cells.  
 
The surviving fractions show that T98G cells are not radiosensitized by both 
CTR-17 and CTR-20 (Figure 32). When radiation was used in the absence of any 
drug, the surviving fractions were 100%, 80%, 85%, 77%, 51% and 39% for 0, 2, 
4, 6, 8 and 10 Gy, respectively. When cells were treated with both radiation and 
CTR-17, the cell viability showed no considerable change, in comparison to 
radiation alone. For example, in the presence of 0.05 µM CTR-17 with 0, 2, 4, 6, 
8 and 10 Gy, the survival fractions were 103%, 82%, 84%, 79%, 61% and 39%, 
respectively. In the presence of 0.2 µM CTR-17 with 0, 2, 4, 6, 8 and 10 Gy, the 
cell viability was 101%, 86%, 87%, 83%, 57% and 39%, respectively.  
  
 
 
 
 
 
 
 
 
 
 
Figure 32: CTR compounds do not radiosensitize T98G cells 
The combination of three different CTR-17 (A) and CTR-20 (B) concentrations 
with increasing doses of radiation introduces no enhanced therapeutic benefit in 
comparison to each treatment modality alone. T98G cells were cultured in 96-
well plates and co-treated with three different concentrations of CTR compounds 
and five different doses of radiation (2-10 Gy). SRB assays were performed after 
72 h. Data presented in the bar graphs are mean ± SEM of two independent 
experiments.    
 
 
 
 
 
 
 
104 
 
A 
Concentration of CTR-17 (M)
S
u
rv
iv
in
g
 F
ra
c
ti
o
n
0 0.05 0.2 0.8
0
50
100
150 0 Gy + CTR-17 2 Gy + CTR-17 4 Gy + CTR-17
6 Gy + CTR-17 8 Gy + CTR-17 10 Gy + CTR-17
 
 
 
B 
Concentration of CTR-20 (M)
S
u
rv
iv
in
g
 F
ra
c
ti
o
n
0 0.01 0.05 0.2
0
50
100
150 0 Gy + CTR-20 2 Gy + CTR-20 4 Gy + CTR-20
6 Gy + CTR-20 8 Gy + CTR-20 10 Gy + CTR-20
 
 
 
105 
 
In the presence of 0.8 µM CTR-17, which is the IC50 for T98G cells, the cell 
viability in combination with 0, 2, 4, 6, 8 and 10 Gy was 53%, 51%, 63%, 70%, 
56% and 41%, respectively.  
 
In addition, the use of CTR-20 together with radiation also did not induce any 
considerable changes to percentage cell survival. For example, in the presence 
of 0.01 µM CTR-20 with 0, 2, 4, 6, 8 and 10 Gy, the survival fractions were 95%, 
77%, 80%, 79%, 57% and 41%, respectively. In the presence of 0.05 µM CTR-20 
with 0, 2, 4, 6, 8 and 10 Gy, the cell viability was 95%, 80%, 86%, 79%, 58% and 
39%, respectively. In the presence of 0.2 µM CTR-20, which is the IC50 for T98G 
cells, the cell viability in combination with 0, 2, 4, 6, 8 and 10 Gy was 54%, 62%, 
75%, 77%, 55% and 40%, respectively.  
 
Together, the data from the combination studies show that both CTR-17 and 
CTR-20 do not radiosensitize the T98G cells. In fact, when the surviving fractions 
are closely analysed for the combinations, in comparison to radiation and drug 
alone, there is a slight inhibitory effect when both the modalities are used in 
combination. This may be because radiation causes a G2 phase arrest (Sui et al. 
2012; Sui et al. 2004) which subsequently abrogates the cytotoxicity of CTR 
compounds that is functional at mitosis as both CTR-17 and CTR-20 are MTAs.  
  
 
 
 
 
 
 
 
4.0 Discussion 
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4.1 Cancer-cell specific cytotoxicity of CTR compounds 
Four CTR compounds were initially short-listed from a series of 75 chalcone-
based derivatives by preliminary cytotoxicity screening performed at the Lee Lab. 
Further studies showed that CTR-17 and CTR-20 inhibited the growth of cancer 
cells 10-25 times more effectively than non-malignant cells (Table 1). In addition, 
Western blot analysis using an anti-PARP antibody showed that CTR-17 induced 
cell death by 48 h post-treatment in HeLa cells but not in 184B5 non-cancer cells 
(Figure 11). As cancer-cell specific cytotoxicity is a highly desirable property for 
the success of anticancer drugs, extensive evaluations on the functional 
mechanisms were carried out as a part of my PhD research project.   
 
Previous studies have recognised the value of chalcones and their derivatives as 
potential anticancer agents.  Several different modes of action by chalcone 
derivatives have been identified including their ability to inhibit MT polymerization 
and angiogenesis, initiation of apoptosis, and overcoming MDR phenotype 
(Ducki 2007). JAI-51 (N-methyl indolyl chalcone), a novel chalcone derivative, 
was shown to possess anti-proliferative effects on one murine and four 
glioblastoma cell lines (Boumendjel et al. 2009). JAI-51 inhibits MT 
polymerization with an added benefit of inhibiting Pgp and MRP drug efflux 
pumps (Boumendjel et al. 2009). However, at least 10 µM JAI-51 needs to be 
used to induce an effective decrease in the proliferation of these cells 
(Boumendjel et al. 2009), which is approximately 33-100 fold higher in 
concentration than the effective concentration of the CTR compounds. 
Modzelewska et al. (2006) evaluated the selective cytotoxic ability of a series of 
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chalcones and bis-chalcones with boronic acid moieties, and found 4-6 fold 
selectivity against breast cancer cells (MDA-MB 231 and MCF-7) over non-
cancer breast cell lines (MCF10A and MCF12A) (Modzelewska et al. 2006). 
Since the discovery of chalcones as potential anti-cancer agents in 1970s 
(Edwards et al. 1990), the specificity towards certain cancer cells and their 
selectivity towards malignant cell lines have been broadly studied.  
 
When considering cell cycle-specific anticancer therapy, anti-mitotic agents 
including paclitaxel and vinblastine are recognised as the most successful drugs, 
partly due to their specific interference of the mitosis with minimal effects on non-
dividing and quiescent cells (Chan et al. 2012) .  However, MTs play an important 
role in different stages of cell cycle, including interphase functions such as axonal 
transport, vesicular trafficking and maintenance of cell shape. Therefore, MTAs 
often render side effects such as myeloid and neurotoxicity due to their damage 
to non-proliferating cells (Schmidt & Bastians 2007). Other anti-mitotic agents 
such as kinase inhibitors (Chk1/2, Cdk1, Aurora A, B, C and Plk1 inhibitors) and 
anti-motor proteins (Eg5 and CENP-E inhibitors) have been extensively studied. 
However, data from clinical trials show that these agents do not meet their initial 
promises (Chan et al. 2012). This may be because: (1) they are active against 
cells only in mitosis and tumor cells residing in interphase are not responsive to 
the cell-killing effects of the drugs; and (2) in patients, the doubling time of tumor 
cells is much longer (about 300 days and 700 days for solid and hematopoietic 
carcinomas, respectively) than cell lines or animal models (about 1-6 and 1-7 
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days, respectively) (Chan et al., 2012; Komlodi-Pasztor, Sackett, & Fojo, 2012). 
Therefore, the success of drugs like paclitaxel is partly attributable to their 
adverse effects on cells in interphase. Hence, an ideal drug would be: (1) cancer-
cell specific by differential permeability or specific target of action (eg: 
monoclonal antibodies) ; and (2) active against vulnerable cell cycle stages (eg: 
mitosis) of proliferating cells, in order to avoid dose-limiting toxicities to the 
normal tissues. 
  
The chalcone derivatives, CTR-17 and CTR-20 are less effective against 
immortalized non-cancer cells (184B5 and MCF10A) as compared to the cancer 
cells hence satisfies one of the requirements for a desirable drug. Secondly, they 
are agents that interfere with the process of mitosis as outlined subsequently, 
hence identifying CTR-17 and CTR-20 as potentially safe and more effective 
anticancer therapeutics. 
 
4.2 CTR-17 and CTR-20 display potent cytotoxicity towards cell lines 
overexpressing MDR or MRP  
Drug resistance is one of the major causes of chemotherapy failures and 
prolonged exposure to a single chemotherapeutic agent often results in the 
emergence of simultaneous resistance towards several different 
chemotherapeutic agents, leading to a phenomenon known as multidrug 
resistance (MDR) (Gottesman et al. 2002). MDR is usually induced by proteins 
that belong to the ABC (ATP-binding cassette) transporter family, including: 
 ABCB1, p-glycoprotein (Pgp) or MDR1 
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 ABCC1 or MDR associated protein-1 (MRP1)  
 ABCG2 or breast cancer resistance protein (BCRP)  
 ABCC2, MRP2 or cMOAT  
 
To determine if CTR-17 and CTR-20 overcome MDR, their cytotoxic properties 
were evaluated using KB-C2, an ABCB1 overexpressing cervical carcinoma cell 
line and H69AR, an ABCC1 overexpressing small cell lung cancer cell line. KB-
C2 cell line was at least 15-fold more resistant to both colchicine and vinblastine 
and more than 10-fold resistant to paclitaxel in comparison to the parental cell 
line (KB-31). In contrast, both CTR-17 and CTR-20 induced cytotoxicity with 
equal potency to both KB-31 and KB-C2. Both CTR-17 and CTR-20 were also 
effective against H69AR cells (Figure 9).  A technical problem faced was that the 
parental H69 cells were always aggregated during cell culturing, making it difficult 
to accurately count cell numbers. To overcome this problem, another small cell 
lung cancer cell line (SW 1271) was used to compare cytotoxic results of H69AR. 
It is evident that CTR compounds overcome MDR, suggesting that these 
compounds may not be substrates for aforementioned drug efflux proteins.  
 
Although the discovery of compounds with a specific target has been the ultimate 
goal of anticancer therapy, there are drawbacks associated with this approach 
(Zhang et al. 2014). The emergence of acquired resistance and dose-limiting 
side effects, limits the continuous application of single drugs (Sams-Dodd 2005). 
Hence, combinations of drugs may provide better results (Lehár et al. 2009). 
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Therefore, the combination of CTR compounds with paclitaxel was explored to 
improve efficacy and overcome MDR (Figure 10). The concentration of the drugs 
used was less than for each drug alone and showed an effective anti-proliferative 
effect. The CI values for six different ratios of CTR compounds to paclitaxel were 
between 0.71-0.87, for CTR-17 with paclitaxel and 0.69-0.95, for CTR-20 with 
paclitaxel. According to previously published reports, all these combinations 
provide synergistic effects as the CI values are below 1 (Chou 2006). Hence, 
each drug could be used at a lower dose to overcome the toxic side effects 
caused by single drugs at high doses, even in the drug-resistant KB-C2 cells.  
  
4.3 CTR-17 is a specific anti-mitotic compound 
Data from flow cytometry profiles showed that CTR-17 treatment for 72 h caused 
a G2/M arrest of 71.6, 61.4 and, 67.4% in HeLa, Hek293T and MDA-MB231 
respectively (It was later found by microscopy and Western blot analysis that the 
arrest point is actually prometaphase-see below). All of these cells eventually 
underwent cell death. For MDA-MB468, the cells accumulated in G2/M phase 
starting from as early as 6 h, and then underwent a massive cell death after 48 h 
of treatment. However, in 184B5 non-cancer cells, only about 25% of cells 
underwent cell death, and the remaining cells progressed a normal cell cycle 
(Figure 12). 
 
The G2/M arrest observed during CTR-17 treatment may actually be; (1) a G2 
arrest that allows time to repair DNA damage before entering into mitosis, or (2) 
a mitotic arrest caused by an aberrant spindle formation (DiPaola 2002). To 
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determine if CTR-17 treatment causes DNA damage or affects DNA replication, 
γH2AX staining and EdU labelling experiments were used. In comparison to 
etoposide, which is a topoisomerase II inhibitor (Baldwin & Osheroff 2005), CTR-
17 did not cause any DNA damage as any γH2AX foci were not observed. CTR-
17 was also not an impediment to DNA replication as no noticeable difference 
was found in EdU labelling patterns in sham vs CTR-17-treated cells (Figure 13). 
Hence, the possibility of a G2 arrest in response to CTR-17 was partially ruled 
out. Western blot analysis further confirmed a mitotic arrest and an inhibition of 
mitotic exit. However, mitotic entry was not impeded (Figures 14 & 17). Further 
studies showed that CTR-17 treatment arrests the cells in mitosis via the 
prolonged activation of the spindle checkpoint (Figure 18), thereby delaying 
mitotic exit by the inhibition of anaphase promoting complex/cyclosome (APC/C) 
ubiquitin ligase activity (Zeng et al. 2010). Previous reports showed that anti-
mitotic agents, especially the MTAs, cause cell death by inducing a prominent 
mitotic arrest via the activation of the spindle checkpoint. It is also suggested that 
if the mitotic arrest is less than 15 h, the cells manage to escape mitosis, leading 
to several other fates (Bekier et al. 2009). In this case, while some cells die in 
interphase others arrest or even survive by undergoing several cycles of cell 
division (Gascoigne & Taylor 2008). This phenomenon is observed with aurora 
kinase inhibitors. The use of an aurora kinase inhibitor, ZM447439, attenuates 
the SAC, which leads to the degradation of cyclin B, mitotic slippage, and re-
replication of genomes (endocycle) (Bekier et al. 2009; Gascoigne & Taylor 
2008). Hence, when cells are treated with anti-mitotic agents, the cell fate is 
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regulated by two competing networks: (1) activation of cell death pathway, and 
(2) prevention of cyclin B degradation. Each of these networks is governed by a 
threshold. If cyclin B degrades below the mitotic exit threshold, the cells undergo 
slippage, however if the cell death threshold is breached first, the cells undergo 
mitotic catastrophe (Gascoigne & Taylor 2008). CTR compounds, similar to other 
MTAs cause a prolonged mitotic arrest which in all cases last longer than 20 h as 
shown previously by the flow profiles and eventually undergoes cell death as 
indicated by the PARP cleavage.  
  
4.4 CTR-17 and CTR-20 are MT polymerization inhibitors 
Additional studies revealed that CTR-17 and CTR-20 disrupt the mitotic spindle 
by inhibiting microtubule polymerisation. Jordan et al. (1992) studied the effects 
of MT depolymerizing drugs namely, vinblastine, podophyllotoxin and nocodazole 
in a concentration-dependent manner. They observed interesting phenotypes 
associated with their mechanism of action: (a) astral MTs were longer and 
denser than in control; (b) few chromosomes remained at the spindle poles 
instead of the metaphase plate; (c) mitotic spindles were shorter than untreated 
cells;  and, (d) centrosomal materials were more fragmented and diffused 
(Jordan et al. 1992). Immunofluorescent staining revealed that CTR-17 and CTR-
20 cause all of these phenotypes. Therefore, the effects on the MTs were studied 
with CTR-17 and CTR-20.  A microtubule polymerisation assay showed that both 
CTR-17 and CTR-20 reduced the polymerisation ability of the MTs (Figure 20). 
The linear segment of the polymerisation curves could be used to calculate the 
Vmax values. The Vmax value for 10.0 µM paclitaxel was 22.8 mOD/min, for G-PEM 
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buffer 6.1 mOD/min, for 3.0 µM CTR-17 4.4 mOD/min and for both 1.0 µM CTR-
20 and 5.0 µM nocodazole, the Vmax values were 3.7 mOD/min. Hence, paclitaxel 
has enhanced the Vmax of the reaction by ~4 fold and CTR compounds and 
nocodazole reduced the Vmax value by ~1.5-2.0 folds relative to the buffer control. 
Therefore, it was concluded that CTR compounds are MT polymerisation 
inhibitors.  
 
Cell treated with CTR-17 were unable to form a normal bipolar mitotic spindle 
and the inter-polar distance between the centrosomes were approximately 35% 
shorter than in the sham-treated HeLa cells. Data from live cell microscopy 
further supported the cell morphology observed by the fixed cells (Figure 21). 
CTR-17 treatment led to the formation of an aberrant mitotic spindle, partly 
because it affects the MT dynamics during mitosis and partly because it reduces 
the MT polymer mass, which then eventually collapse into a monopolar-like 
spindle. Differential extraction of polymerised and soluble pools of tubulin further 
confirmed the ability of the CTR compounds to inhibit MT polymerization. 
Paclitaxel (50 nM) enhanced the polymerised pool of tubulin by 90%. In contrast, 
nocodazole (50 ng/ml) reduced the polymerized pool by 80% and the two CTR 
compounds by ~50%. Both CTR-17 and CTR-20 also enhanced their 
depolymerising ability in a dose-dependent manner. Further, the phenomenon 
was observed in two other cell lines, namely MDA-MB231 and MDA-MB468, 
suggesting that the MT depolymerizing ability of these compounds is a general 
mechanism in cancer cells (Figure 22). 
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Numerous reports have shown the involvement of MTs in cell migration, and 
since cell migration plays a vital role in tumor metastasis, the use of MT inhibitors 
to prevent cell movement is widely studied (Schwartz 2009; Palmer et al. 2011; 
Goldman 1971; Vasiliev et al. 1970). CTR-17 not only reduced the degree of 
wound closure but also reduced the average velocity of the migration of MDA 
MB-231 cells. These findings strongly agree with previous reports of cell 
migration inhibition by MTAs such as colchicine and colcemid (Goldman 1971; 
Vasiliev et al. 1970). Additional studies showed that inhibition of cell locomotion 
is not necessarily due to the reduction of the MT polymer mass but due to the 
poor dynamics of MTs (Yang et al. 2010). Another study by the same group 
showed the involvement of MTs in cell migration using a simplified model 
(Ganguly et al. 2012). The authors’ observations are summarized below. (1) In a 
normally migrating cell, lamellipodia occurs in random directions. In the presence 
of chemotactic signals, MT dynamics are suppressed in a particular region of the 
cells, causing MT stabilization and disruption of the lamellipodia retraction, which 
then allows the establishment of lamellipodia in the leading edge of the cells. 
MTs directed towards the forward direction of the cells aid in the feeding of the 
cells’ leading edge via the distribution of vesicles. These MTs are higher in 
density but lower in their dynamicity. However, MTs at the trailing end of the cell 
are more dynamic and undergo rapid remodeling, which will allow the cell to 
retract the tail of the cell, allowing the cell to move in the forward direction. This 
cellular polarity permits the cells to either move along a chemical gradient or 
even during wound closing process. (2) In the presence of drug in low 
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concentrations, MT dynamics are abrogated globally; hence, the MTs towards 
the trailing edge of the cell are less capable of remodelling. This causes the cells 
to polarize but are not able to retract their trailing edge, disrupting the forward 
migration of the cell. (3) In the presence of drug at high concentrations, MTs are 
completely eliminated. Nevertheless, there are short-lived lamellipodia and cells 
can move in the directionless fashion.  
 
Therefore, in the presence of MTAs such as CTR-17, cell motility can either be 
completely abrogated or directionless, suggesting a possible role of CTR 
compounds in suppressing tumor metastasis (Figure 23).  
 
4.5 The binding sites of CTR-17 and CTR-20 to tubulin largely overlap with 
that of colchicine-binding site 
The goal was then to determine if CTR compounds directly bind to tubulin protein 
by fluorescence microscopy. Fluorescence microscopy is one of the most 
sensitive approaches to evaluate the properties of different biological systems 
based on the changes incurred by various structural and molecular properties 
(Guha et al. 1996). Each tubulin dimer consists of eight tryptophan residues 
which emits an intrinsic fluorescence when excited at 295 nm. The presence of a 
ligand that binds to tubulin may directly cause the quenching of the intrinsic 
fluorescence, which could be used as a probe to determine the binding constant 
(Bhattacharyya et al. 1993).  CTR-17 and CTR-20 reduced the intrinsic 
tryptophan fluorescence of tubulin, and the Kd values were found to be 4.58±0.95 
µM and 5.09±0.49 µM for CTR-17 and CTR-20, respectively, indicating that CTR 
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compounds directly bind to tubulin (Figure 24). CTR-17 and CTR-20 bind to 
tubulin with stronger affinity than other MTAs such as vinblastine (Kd of 43 µM) 
(Lee et al. 1975), estramustine (Kd of 30 µM) (Panda et al. 1997) and dolastatin 
15 (Kd of 30 µM)  (Cruz-Monserrate et al. 2003; Ludueña et al. 1992). However, 
binding of CTR-17 and CTR-20 is weaker than colchicine which binds with a 
dissociation constant of 0.5 µM (Panda et al. 1992). This strong affinity of 
colchicine to tubulin leads to a poorly reversible colchicine-tubulin complex. 
Hence, the cytotoxic effects caused by colchicine are irreversible, hampering the 
use of colchicine as a chemotherapeutic agent (Thomas et al. 2014; Dumontet & 
Jordan 2010). CTR-17 and CTR-20, on the other hand, are reversible mitotic 
agents as shown in Figure 19. This might be due to: (1) reversible binding of 
CTR compounds to tubulin; or (2) absence of long-term retention within cells. 
Hence CTR-17 and CTR-20 may be safer drugs to be used in anticancer 
therapy. 
 
There are a number of other chalcone derivatives that directly bind to tubulin and 
their degree of binding varies significantly. For example, JAI-51 (Kd of 5.0 µM) 
exhibits a similar binding ability to tubulin as the CTR compounds (Boumendjel et 
al. 2009). However, (E)-3-(6-Chloro-2H-chromen-3-yl)-1-(3,4,5-trimethoxy 
phenyl)prop-2-en-1-one, also known as compound 14 (Kd: 9.4 µM) (Aryapour et 
al. 2012) binds to tubulin with a lower affinity while MDL-27048 (Kd: 0.36 µM) 
(Peyrot et al. 1992; Peyrot et al. 1989) binds to tubulin with a much higher affinity 
than the two CTR compounds.  
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MT polymerisation inhibitors generally interact with tubulin through either the 
colchicine or vinblastine-binding site (Dumontet & Jordan 2010; Singh et al. 
2008). Vinblastine-binding site was initially examined to determine if the two CTR 
compounds bind to tubulin via the same site, using a fluorescent analogue of 
vinblastine, BODIPY® FL Vinblastine. When BODIPY® FL Vinblastine binds to 
tubulin, the fluorescence intensity was enhanced, which was quenched by a 
compound that binds close to or at the vinblastine-binding site (eg: vinblastine). 
However, neither the CTR compounds nor colchicine were able to inhibit the 
fluorescence development of BODIPY® FL Vinblastine-tubulin complex, 
suggesting that CTR compounds and colchicine do not bind to the vinblastine 
site. (Figure 25A)  
 
Therefore, the possibility of binding of the two CTR compounds to the colchicine-
binding site was then examined. Intrinsic fluorescence of colchicine increases 
upon forming the tubulin-colchicine complex which could be used as an index to 
evaluate the competition between colchicine and CTR compounds to bind to the 
colchicine-binding site (Bhattacharyya & Wolff 1974). Both the CTR compounds 
dose-dependently quenched the intrinsic fluorescence of the colchicine-tubulin 
equilibria, suggesting that both CTR-17 and CTR-20 bind at or near the 
colchicine-binding site. CTR-17 and CTR-20 competitively inhibited the binding of 
colchicine with a Ki of 5.68±0.35 µM and 1.05±0.39 µM, respectively, as 
determined by modified Dixon plots. Ki value indicates the degree of potency of 
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an inhibitor (Burlingham & Widlanski 2003). In this case, the concentration of 
CTR-20 required to inhibit half of the maximum colchicine binding was 
approximately five times less than CTR-17 (Figure 26). This suggests that CTR-
20 binds to the colchicine site more strongly than CTR-17, which also further 
assured by docking analysis as is discussed below. 
  
Molecular modeling data revealed that the binding sites of both CTR-17 and 
CTR-20 on the tubulin largely overlap with that of colchicine or podophyllotoxin, 
but distinct to the vinblastine-binding site (Figures 27 & 28). In binding, many 
amino acids are shared among colchicine and the two CTR compounds, 
according to the prediction of ligand interactions. Hence, it is reasonable to 
assume that CTR-17 and CTR-20 occupy a site very close to the colchicine-
binding site to tubulin. However, the mode of binding may be different among the 
three compounds. Colchicine forms three H-bonds, and CTR-17 and CTR-20 
form only one and two H-bonds, respectively. It is possible that these differences 
may lead to changes in the efficacy, toxicity and reversibility of colchicine versus 
the CTR compounds.  
 
4.6 Why are CTR compounds selective towards cancer cells? 
To determine the selectivity of CTR compounds, their efficacy on twelve cancer 
cell lines and two non-cancer cell lines (184B5 and MCF10A) was compared. 
CTR-17 and CTR-20 were approximately 10-25 fold more selective in killing 
cancer cells than the non-cancer cells. To probe the mechanism of selectivity of 
the CTR compounds, the doubling time of different cell lines were evaluated to 
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examine whether the selectivity is rendered by fast growth. However, the 
doubling times of cancer and non-cancer cells were largely similar (Figure 29 and 
Table 6). In addition, linear regression analyses indicated that no relation exists 
between the cytotoxicity caused by both CTR compounds and the doubling times 
of different cells (Figure 30). Therefore, cancer cell selectivity of the CTR 
compounds is not due to differences in cell proliferation rates.  
 
To gain better insight into their cancer cell selectivity, the intracellular 
concentration of CTR-17 in MDA-MB231 (cancer) and 184B5 (non-cancer) cells 
(Figure 31) was examined. There was no significant difference in the quantity of 
CTR-17 in the two different cell lines, suggesting that the permeability of CTR-17 
is similar for both cancer and non-cancer cells. Hence the selectivity of the two 
CTR compounds needs to be further elucidated at this point and requires 
additional investigation.  
 
4.7 Combination of CTR compounds and radiation shows no improved 
cytotoxicity  
When increasing doses of radiation was administered in combination with both 
CTR-17 and CTR-20 to T98G cells, there was no enhancement in the cytotoxicity 
of each treatment modality (Figure 32). In fact, when both the CTR compounds 
were used at their IC50 concentration, in combination with radiation, the 
cytotoxicity was reduced in radiation doses, 4, 6, and 8 Gy. For example, in the 
absence of any radiation, 0.8 µM of CTR-17 led to 50% cell viability. When CTR-
17 was used at the same concentration in combination with 4, 6, and 8 Gy, 
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however, the survival fractions increased to 63%, 70% and 56%, respectively. In 
addition, when 0.2 µM of CTR-20 was used alone, the cell viability was 54%. In 
contrast, when CTR-20 was at the same concentration in combination with 2, 4, 
and 6 Gy, the survival fractions increased to 62%, 75%, and 77%, respectively. 
Therefore, the combination of radiation and CTR compounds show no enhanced 
cytotoxicity but a slight reduction in efficacy.  
 
The above combinational effect has been previously demonstrated using other 
microtubule drugs, including paclitaxel and vinblastine. The use of paclitaxel in 
combination with radiation has shown cell cycle-dependent antagonistic effects 
(Sui et al. 2004). Further, the combination of vinca alkaloids, including vincristine 
and vinblastine along with radiation was shown to antagonise the cytotoxic 
effects in both breast and human epidermoid cancer cells (Sui & Fan 2005). This 
may be because radiation causes G2 arrest, which is prior to the CTR functional 
point. Additionally, the presence of UCN-01 which leads to the abrogation of G2 
checkpoint was shown to inhibit the radiation-induced arrest in the G2 phase. 
This led to the reduction in the radiation-induced inhibition on mitotic arrest and 
apoptosis, causing an enhanced cytotoxicity in breast (BCap37) and human 
epidermoid (KB) cancer cells (Sui et al. 2012).  Hence, if CTR compounds were 
eventually to be used in combination with radiation, the use of a G2 checkpoint 
inhibitor may be necessary.  
4.8 Conclusion  
In conclusion, data presented in this thesis suggest that CTR-17 and CTR-20, 
novel chalcone derivatives, have a broad range of anti-tumor activity. The two 
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CTR compounds induce a prominent mitotic arrest through inhibition of MT 
polymerisation, which is caused by their binding to tubulin at the colchicine-
binding site. It is important to recognise that CTR-17 and CTR-20 exert lesser 
toxicity to normal cells than colchicine, a highly desirable property for better 
therapeutic index. This is because CTR-17 and CTR-20 preferentially kill cancer 
cells over non-cancerous cells, despite the cell doubling times of cancer and non-
cancerous cells examined were largely indistinguishable. Thus, CTR-17 and 
CTR-20 can be extremely desirable anticancer drugs. 
 
A large number of the clinically efficient anticancer drugs are MTAs (Gascoigne & 
Taylor 2009). These anti-mitotic agents target the shortest but the most elaborate 
phase of the cell cycle. Although MTAs effectively target mitosis, interphase cells 
are also susceptible to microtubule inhibitors. Hence, MTAs usually lead to 
myelosuppression and cause neurotoxicity that could sometimes lead to 
permanent damage in central and peripheral nervous systems  (Rowinsky et al. 
1993). Apart from the deleterious side effects, currently available clinically 
successful drugs including taxanes and vinca alkaloids lead to innate and 
acquired resistance. Hence, the goal of modern anticancer therapy is the 
development of novel agents that are more specific to tumor cells and could also 
overcome multidrug resistance. The combination of CTR compounds and 
paclitaxel in treating MDR cells induces a synergistic anti-proliferative effect, 
even at low drug concentrations (nM range). Therefore, each of these drugs 
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could be used at low doses which, in turn, may overcome undesirable side 
effects. 
  
Further studies, using a xenograft model of the human breast cancer cells, 
showed CTR-17 and CTR-20 can indeed be effective and safe drugs, when used 
alone or in combination with paclitaxel. In particular, the combination of 5.0 
mg/kg body weight of paclitaxel and 15.0 mg/kg body weight of CTR-20 could 
completely inhibit tumor growth in nude mice engrafted with the MDA MB-231 
metastatic breast cancer cell line (This animal-based study was carried out by 
another lab member).  
 
The findings of this thesis put forth an elaborative elucidation of the mechanistic 
effects of CTR-17 and CTR-20. These novel MTAs are not only selective but also 
overcome MDR. Therefore, both CTR-17 and CTR-20 could be used as 
attractive lead compounds to perform further structural modifications.  
 
4.9 Future Directions 
CTR compounds are potential anticancer therapeutics, which hold much promise 
for the future. Both CTR-17 and CTR-20 are cancer-cell specific, which is a 
highly desirable property as anticancer agents. In addition, the two CTR 
compounds effectively kill MDR cells when used alone or in combination with 
paclitaxel, hence they could be used as potential drug candidates to minimise 
acquired resistance to currently available drugs including paclitaxel and 
vinblastine. CTR-17 and CTR-20 are reversible MTAs that reduce the 
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polymerization of tubulin. It should be noted that MTs are a well-validated target 
for anticancer therapy. Highly proliferating cells, such as cancer cells are more 
vulnerable to MTAs than normal tissues which only replicate to replace dead 
cells. Nevertheless many MTAs impose a certain degree of toxicity to normal 
cells (Stanton et al. 2011).  Hence, CTR compounds are MTAs with unique 
benefits of selectivity, overcoming MDR, and reversibility.  
 
However, it would still be desirable to evaluate the potential of CTR compounds 
in combinatorial therapies, as no single agent is used as a cure for cancer. 
Multimodal therapies offer enhanced long-term prognosis and may reduce side 
effects. Combinatorial therapies involve either the combination of two treatment 
modalities (chemotherapy and radiotherapy) or the simultaneous administration 
of two or more pharmacologically efficient drugs. The use of a combinatorial 
regimen can modulate multiple signalling pathways, and enhance the therapeutic 
benefits, while possibly reversing the resistance mechanisms (Greco & Vicent 
2009).   
 
Two different screening approaches can be implemented to determine the most 
effective combinatorial regimen for CTR compounds. Firstly, a biased screening 
approach can be used, during which currently available chemotherapeutics and 
other treatment modalities; such, as radiation can be explored in combination 
with CTR compounds, which will in part be based on previously published 
reports. Data from Figure 32 showed that the co-administration of radiation and 
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CTR compounds did not radiosensitize T98G cells. However, there are number 
of additional factors that influence the combinatorial effects of radiation and 
anticancer compounds, including duration and concentration of drugs, different 
cancers, different radiation schedule, and sequence of drug and radiation 
administration (Pawlik & Keyomarsi 2004). Therefore, these factors may be taken 
into consideration when performing further combination experiments of CTR 
compounds with radiation and other regimens. 
 
Paclitaxel when used in combination with CTR compounds synergistically killed 
KB-C2 MDR cells, illustrating the role of CTR compounds in overcoming 
resistance (Figure 10). A previous study identified a synthetic lethal interaction 
between MT destabilizing drug, vinblastine and BCL-2 inhibitor, ABT-263 that 
enhanced the cytotoxicity against glioblastoma and non–small-cell lung cancer 
cells (Kitchens et al. 2011). Another study showed a synergistic induction of 
apoptosis by vinblastine and BI2536, a Plk1 inhibitor in rhabdomyosarcoma 
(RMS) cells and in vivo RMS models (Hugle et al. 2015). Since the mode of 
action of CTR compounds is similar to vinblastine, irrespective of different 
binding sites, the combination of CTR and ABT-263 (or BI2536) might 
substantially enhance efficacy. 
 
Secondly, an unbiased siRNA screening approach can also be used to identify a 
novel target that may render synergistic effect when blocked the target in the 
presence of CTR. siRNA technology is widely used for determining the essential 
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genes required for the survival of cancer cells. By using siRNA synthetic lethality 
screening methods, we can elucidate certain proteins or signals that can 
effectively kill cancer cells when inhibited in the presence of CTR (Whitehurst et 
al. 2007). For initial assays, MDA-MB231 human breast cancer cells may be 
used in a CTR-20-dependent synthetic lethality screen. We can identify gene 
products that render cell survival in the presence of CTR-20 by siRNA high 
throughput sequencing in combination with stringent statistical analysis. If 
pharmacological inhibitors for the gene products are available, validation and 
further combination assays may be performed with CTR-20 to determine the 
most effective combinatorial regimen.  
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 Table A1: List of antibodies used 
Primary 
Antibody 
Company 
Cat 
Number 
Dilution Application 
α-Tubulin 
Santa Cruz sc-8035 1:200 Western blotting 
α-Tubulin 
Santa Cruz sc-53030 1:500 Immunofluorescence 
β-Actin 
Santa Cruz sc-47778 1:200 Western blotting 
γ-Tubulin 
Santa Cruz sc-7396 1:500 Immunofluorescence 
γ-H2AX 
Abcam ab 11174 1:500 Immunofluorescence 
BubR1 
Abcam ab 4637 1:50, 3µg/1mg 
protein, 1:1000 
Immunofluorescence, 
Immunoprecipitation & Western  
Cdc20 
Abcam ab 18217 1:200 Western blotting 
Cdc25C 
Santa Cruz sc-327 1:200 Western blotting 
Cdk1 
Santa Cruz sc-137034 1:200 Western blotting 
Cenp-B 
Abcam ab 25734 1:50 Immunofluorescence 
Cleaved PARP 
Santa Cruz sc-56196 1:200 Western blotting 
Cyclin A 
Santa Cruz sc-271682 1:200 Western blotting 
Cyclin B 
Santa Cruz sc-245 1:200 Western blotting 
Cyclin E 
Santa Cruz sc-198 1:200 Western blotting 
Gapdh 
Santa Cruz sc-47724 1:200 Western blotting 
Histone H3 
Santa Cruz sc-10809 1:200 Western blotting 
Normal IgG 
Santa Cruz sc-2027 3µg/1mg protein Immunoprecipitation 
PARP 
Santa Cruz sc-8007 1:200 Western blotting 
p-Cdc25C,T48 
Cell Signalling 9527 1:1000 Western blotting 
p-Cdc25C,S216 
Abcam ab 32051 1:1000 Western blotting 
p-Cdk1,T161 
Santa Cruz sc-12341 1:200 Western blotting 
p-Cdk1,Y15 
Santa Cruz sc-7989 1:200 Western blotting 
p-Histone H3, S10 
Santa Cruz sc-8656 1:200 Western blotting 
MDR1 
Santa Cruz sc-1517 1:200 Western blotting 
MRP1 
Santa Cruz sc-18835 1:200 Western blotting 
Securin 
Abcam ab-3305 1:1000 Western blotting 
Wee1 
Santa Cruz sc-5285 1:200 Western blotting 
 
